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Preface 
 
My main scientific area of interest is lymphocyte biology specifically in the settings of 
immunodeficiencies. I started working in human T cells at the Unidade de Imunologia 
Clínica of the Instituto de Medicina Molecular with Prof. Doutora Ana Espada de Sousa, 
where I had the opportunity to develop a project on T cell production during HIV-2 infection. 
This project focused on a natural model of attenuated HIV disease and generated important 
results on the role of IL-7 and the contribution of the thymus for the understanding of 
HIV/AIDS pathogenesis that were published in: 
 
“Rate of increase in circulating IL-7 and loss of IL-7Ralpha expression differ in HIV-1 and 
HIV-2 infections: two lymphopenic diseases with similar hyperimmune activation but distinct 
outcomes.”(J.Immunol 2007, 178, 3252-9).  
 
“Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T cells during 
chronic human immunodeficiency virus type 2 infection”. (J.Virol 2007, 81, 12685-8).  
 
After developing this study in human immunodeficiency, I was offered the possibility to 
develop research in a murine model of B cell immunodeficiency, at the Transplantation 
Biology Unit, Mayo Clinic, with Prof. Doutora Marília Cascalho. The work done with a 
murine model of TACI knockout generated data that contributed to the understanding of the 
role of TACI in the differentiation of plasma cells upon antigenic stimulation, and resulted in 
the publication: 
 
“TACI is required for efficient plasma cell differentiation in response to T-independent type 2 
antigens.”( J Immunol 2007, 179, 2282-8). 
 
Thus, the present thesis is organized into two Parts. Part I is entitled “T-cell production in 
HIV-2 infection: insights to AIDS pathogenesis” and Part II is entitled “TACI regulation of B 
cell differentiation after antigenic stimulation”. Given the distinct topics studied, each part 
includes an Introduction / State of the Art, a Result section comprising the published papers 
and a section summarizing the Conclusions and Future Perspectives.  
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In conclusion, it is clear to me that these two different experiences during my Ph.D. were 
critical for my development as a scientist. I had the opportunity to work in basic and clinical 
science, in two completely different systems, human studies and mouse knockout models, 
which allowed me to learn an array of different techniques. Also, it has brought me closer to 
different forms of scientific reasoning, as well as new ways of posing scientific questions and 
design of experiments to answer them.  
 
Lisbon, 2009 
Catarina dos Santos Cortesão 
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Resumo 
Neste trabalho foram investigados alguns mecanismos que contribuem para a manutenção de 
imunocompetência usando dois modelos: um modelo humano natural atenuado da síndrome 
da imunodeficiência adquirida (SIDA), a infecção pelo HIV-2; e um modelo murino de 
deficiência de células B por defeito de TACI (Transmembrane Activator and Calcium 
Modulating Cyclophilin Ligand Interactor). 
 
A Parte I deste trabalho intitulada “Produção de células T durante a infecção pelo HIV-2” 
teve por objectivo estudar o impacto da infecção pelo Vírus da Imunodeficiência Humana 
tipo 2 (HIV-2) na maturação das células T no timo e na sua diferenciação na periferia. A 
epidemia HIV/SIDA constitui actualmente um dos principais problemas de saúde, estimando-
se que entre 1981 e 2007 aproximadamente 65 milhões de pessoas foram infectadas em todo 
o mundo. Os agentes responsáveis pela SIDA são o HIV-1 e HIV-2. A infecção por HIV-1 é 
caracterizada por uma inexorável depleção das células T CD4, para a qual contribuem vários 
factores além de efeitos citopáticos do vírus. Independentemente dos mecanismos envolvidos 
na depleção das células T CD4, um factor determinante do ritmo de progressão da doença é a 
capacidade de reconstituição do compartimento de células T. Num indivíduo saudável, a 
manutenção da população de células T é assegurada por mecanismos homeostáticos que 
regulam a proliferação e sobrevivência de células na periferia, conjuntamente com a 
produção de linfócitos no timo, sendo a contribuição tímica dependente da idade. A infecção 
pelo HIV-1 associa-se a alterações da produção de novo de células T e, por outro lado, a uma 
activação imunitária persistente que compromete os mecanismos de proliferação 
homeostática. Na infecção por HIV-2, a progressão da doença é mais lenta do que por HIV-1 
associando-se a um impacto limitado na sobrevivência da maioria dos adultos infectados. A 
infecção por HIV-2 caracteriza-se por um ritmo de perda das células T CD4 menos acentuado 
e por menor carga viral circulante, embora os níveis de activação imunitária sejam 
semelhantes nos doentes infectados pelo HIV-1 e pelo HIV-2 com grau de depleção de 
células T CD4 comparável.  Deste modo, a infecção por HIV-2 pode ser considerada um 
modelo natural de doença HIV “atenuada”.  
 
O primeiro objectivo deste trabalho foi estudar o papel da interleucina 7 (IL-7), uma citocina 
essencial para a homeostasia das células T, em situações clínicas de linfopenia provocadas 
pela infecção pelo HIV-2. Os níveis séricos de IL-7 foram quantificados por ELISA e 
determinou-se a expressão da cadeia α do seu receptor (IL-7Rα) em células T CD4 e CD8 
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por citometria de fluxo, num estudo transversal envolvendo grupos de doentes infectados 
pelo HIV-2 e doentes infectados pelo HIV-1, equiparados para idade e estadio da doença. Os 
resultados documentaram uma correlação entre os níveis séricos de IL-7 e o grau de depleção 
de células T CD4 na infecção pelo HIV-2, que se revelou significativamente mais forte do 
que a observada na infecção pelo HIV-1, sendo esta semelhante à documentada em outros 
cohorts de doentes infectados pelo HIV-1. É importante realçar que na fase inicial da 
infecção por HIV-2 os níveis séricos de IL-7 não diferem do grupo controlo de indivíduos 
saudáveis, ao contrário dos níveis elevados documentados nos doentes infectados pelo HIV-
1. Nos estadios mais avançados, os níveis séricos de IL-7 apresentam-se significativamente 
aumentados em ambas as infecções em comparação com o grupo de controlos saudáveis. Em 
relação ao receptor IL-7Rα documentou-se uma melhor preservação da sua expressão nas 
diferentes sub-populações de células T, em particular nas células T CD4 naive, nos doentes 
infectados pelo HIV-2. Estes resultados sugerem uma maximização da utilização dos recursos 
de IL-7 disponíveis durante a infecção pelo HIV-2.  
 
O timo é essencial para o desenvolvimento e maturação das células T, contribuindo assim 
para manter a diversidade do repertório do receptor das células T (TCR). Esta diversidade é 
considerada fundamental para montar respostas contra novos agentes patogénicos e para 
prevenir a evasão de microorganismos persistentes às respostas do sistema imunitário. Apesar 
de o timo involuir com a idade, é actualmente reconhecida a funcionalidade do timo adulto, 
principalmente em situações clínicas em que há necessidade de reconstituir as populações de 
células T na periferia. Não existem estudos sobre a função tímica na infecção pelo HIV-2. É 
plausível admitir que o melhor curso da infecção pelo HIV-2 seja devido, em parte, a uma 
melhor capacidade do timo de compensar a perda de células T e de manter na periferia uma 
maior diversidade do repertório do TCR. A função tímica pode ser avaliada através da 
quantificação de pequenos fragmentos de DNA epissómico designadas T-cell receptor 
excision circles (TREC), resultantes dos rearranjos, na timopoiese, dos genes das cadeias que 
compõem o TCR. Durante a maturação das células T αβ, ocorre o rearranjo do gene da 
cadeia β seguido do rearranjo do gene da cadeia α, originando, respectivamente,  βTREC e 
sjTREC entre outros. A proliferação celular que ocorre entre estes dois rearranjos é o 
principal determinante do número de timócitos gerados no timo. Como os níveis de TREC se 
diluem progressivamente com a proliferação celular, a quantificação do rácio sj/β TREC nas 
células do sangue periférico permite estimar a dinâmica proliferativa intratímica e, desta 
 23 
 
Resumo 
forma, indirectamente a produção de linfócitos T no timo. Assim, no segundo objectivo 
proposto para esta parte do trabalho, utilizou-se esta metodologia para estimar a função 
tímica em grupos de doentes infectados com HIV-2 e doentes infectados com HIV-1, 
correlacionando-a com parâmetros de progressão da doença. Tal como esperado, os 
indivíduos saudáveis apresentaram uma diminuição do rácio sj/βTREC de acordo com a 
idade, sendo estes valores significativamente inferiores na infecção pelo HIV-1. Nos doentes 
infectados pelo HIV-2 documentou-se uma relativa manutenção do rácio sj/β TREC com a 
idade.  
 
Em conclusão, os resultados aqui apresentados sugerem que na infecção pelo HIV-2, quer a 
timopoiese quer a homeostasia das células T na periferia estão menos comprometidas, 
podendo contribuir para um ritmo de progressão da doença mais lento. Estes resultados 
enfatizam o papel do timo como alvo terapêutico para uma completa reconstituição 
imunitária em conjugação com terapêutica anti-retroviral na infecção pelo HIV-1.  
 
A Parte II deste trabalho, intitulada "Regulação pelo TACI da diferenciação de células B após 
estimulação antigénica”, teve por objectivo geral clarificar o papel da molécula TACI na 
diferenciação de células B. Esta molécula é uma proteína transmembranar tipo III da 
superfamília dos receptores do TNF (Tumor Necrosis Factor), expressa em células B. A sua 
importância tem sido evidenciada em estudos de modelos de ratinho com deficiência em 
TACI onde se observam infecções bacterianas recorrentes do tracto respiratório e 
hipogamaglobulinemia, designadamente de IgG e IgA, atribuídas a uma disfunção das células 
B. A deficiência em TACI foi recentemente associada a Imunodeficiência Comum Variável 
(IDCV), um grupo heterogéneo de doenças caracterizadas por deficiência de produção de 
anticorpos. Estima-se que 5% a 10% dos doentes diagnosticados com IDCV têm pelo menos 
uma mutação no locus TNFRSF13B que codifica o TACI.  
 
Com o objectivo de clarificar de que forma o TACI promove a produção de anticorpos, 
examinou-se o efeito da deficiência de TACI num modelo de ratinho em que a maioria das 
células B produz um anticorpo especifico para o hapteno 4-hydroxy, 3-nitro-phenylacetic 
acid (NP), o modelo Quasi-Monoclonal (QM). Os ratinhos QM TACI KO e QM TACI+ 
foram imunizados com NP-Ficoll, que activa as células B na ausência de ajuda das células T 
e por essa razão se denomina um estimulo T-independente. A frequência de células B 
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produtoras de anticorpos foi avaliada por ELISPOT e os anticorpos produzidos foram 
quantificados por ELISA. Neste ratinho observou-se que a deficiência em TACI nas células B 
causa uma diminuição no numero de células produtoras de IgM e IgG específicas para NP em 
resposta a NP-Ficoll. Determinou-se que a origem do defeito na produção de anticorpos 
reside no estadio precedendo a diferenciação em plasmócitos. De facto, deficiência em TACI 
não diminui a intensidade e frequência de activação ou proliferação das células B quando 
estimuladas por NP-Ficoll. Pelo contrário, células B deficientes em TACI permaneceram em 
ciclo celular durante mais tempo e produziram clones maiores do que células B TACI+ após 
imunização com NP-Ficoll sugerindo controle da expansão clonal por TACI. 
 
Estes resultados sugerem que TACI exerce duas funções autónomas nas células B: por um 
lado, controla o número de ciclos de proliferação após activação; por outro lado, estimula a 
diferenciação das células B em plasmócitos. Assim, este estudo contribuiu para clarificar o 
aparente paradoxo que envolve o papel simultaneamente activador e inibidor do TACI na 
função das células B. 
 
 
Palavras Chave: HIV/AIDS; HIV-2; IL-7/IL7R-α; Timo; TREC; TACI; respostas de células 
B independentes de T; diferenciação de plasmócitos. 
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This work aimed to investigate mechanisms that contribute to the maintenance of immune 
competence using two models: the HIV-2 associated immunodeficiency and a murine model 
of B cell immunodeficiency, the TACI (Transmembrane Activator and Calcium Modulating 
Cyclophilin Ligand Interactor) deficiency. 
 
Part I, entitled “T cell production in HIV-2 infection: insights to AIDS pathogenesis”, was 
designed to study the impact of infection with HIV-2 on T cell maturation in the thymus and 
on their differentiation in the periphery in order to provide insights into HIV/AIDS 
pathogenesis. AIDS epidemic represents one of the most important health problems world-
wide. Between 1981, when the first AIDS patients were described, and 2007, approximately 
65 million cases of HIV infection have been diagnosed and 25 million people have died of 
AIDS-related illnesses. The viral agents responsible for AIDS are HIV-1 and HIV-2. HIV-1 
infection is characterized by a progressive and relentless decline of CD4 T cells and this 
depletion cannot be solely attributed to the directed effects of cell infection by the virus per 
se. Regardless of the mechanisms involved in CD4 T cell depletion, the replenishment of the 
T cell pool is a major determinant of disease progression. In a healthy state, the maintenance 
of the naive T cell pool is currently thought to be due to homeostatic mechanisms that control 
proliferation and survival of peripheral T cells combined with an age-dependent contribution 
of thymic output. Importantly, de novo T cell production in the thymus is impaired by HIV-1 
infection. Additionally, the HIV-associated persistent hyper-immune activation is known to 
increase susceptibility to apoptosis and to impair peripheral T cell proliferation as well as to 
increase the outflow of naive T cells into the memory-effector compartment. HIV-2 infection 
is characterized by a progressive CD4 T cell decline that is much slower than in HIV-1 
infection, but features similar levels of hyper-immune activation throughout the natural 
history of the disease, despite the reduced viremia. Therefore, HIV-2 was used in this work as 
a model of “attenuated” HIV disease to provide insights into the alterations of the 
mechanisms necessary for the replenishment of the T cell pool during HIV/AIDS 
pathogenesis. 
 
The first objective was to address the role of interleukin 7 (IL-7), a nonredundant cytokine for 
T cell homeostasis, in lymphopenic clinical settings associated to HIV-2. It has been 
previously shown that IL-7 levels correlate with CD4 T cell depletion during HIV-1 
infection. Serum IL-7 was quantified by ELISA and the expression of the α chain of the IL-7 
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receptor (IL-Rα) in CD4 and CD8 T cells was assessed by flow cytometry, in a cross-
sectional study involving HIV-2 and HIV-1 cohorts of patients paired for disease stage. A 
strong positive correlation was documented between circulating IL-7 levels and the degree of 
CD4 T cell depletion in HIV-2 infection. Moreover, in contrast to HIV-1 infection, the levels 
of circulating IL-7 were not significantly increased in the early stages of HIV-2 infection. On 
the other hand, at advanced stages, similar levels of circulating IL-7 were found in both HIV-
2 and HIV-1 cohorts, which were significantly higher than the ones found in seronegative 
controls. In relation to the IL-7 receptor, a clear better preservation of IL-7Rα expression was 
documented in different lymphocyte T sub-populations in the HIV-2 infected cohort, in 
particular within the naive CD4 T cell pool. Overall, the data suggest a maximization of 
available IL-7 resources in HIV-2 infection. 
 
The thymus provides a unique environment for T cells to mature and to generate a highly 
diverse repertoire of T cell receptors (TCR). Diversity of the TCR repertoire is considered 
necessary for recognition of all possible “invaders” and for mounting adequate specific 
responses to persistent pathogens in order to prevent escape. There is increasing evidence for 
the functional capacity of the adult thymus, particularly in clinical settings in which the T cell 
pool needs to be regenerated, despite thymic involution with age. There are no studies on 
thymic function in HIV-2 infection. It is conceivable that a better ability of the thymus to 
compensate the loss of naive T cells and to maintain a diverse TCR repertoire could 
contribute to the distinct course of the HIV-2 disease. T cell receptor excision circles (TREC) 
are small episomal DNA molecules excised from the genome of T cells during the 
rearrangement of their TCR in the thymus. The rearrangements of the loci of β and α chains 
of the TCR occur sequentially, generating βTREC and sjTREC, respectively. The cellular 
proliferation that occurs between these two recombination events is a major determinant of 
thymic output. Since TREC levels are diluted down during cell proliferation, the 
quantification of the ratio between β and sj TREC in peripheral cells gives an estimative of 
the intrathymic cellular division history that correlates with thymic output. 
 
The second objective was to estimate thymic activity by measuring intrathymic proliferation 
history of circulating lymphocytes through the quantification of sj/β TREC ratio in order to 
evaluate a possible thymic contribution to the long term maintenance of peripheral CD4 T 
cells during HIV-2 infection. β and sj TREC levels were quantified in peripheral blood T 
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cells from HIV-2 and HIV-1 chronically infected patients without antiretroviral treatment. In 
seronegative controls there was a reduction in the sj/β TREC ratios with age in agreement 
with the expected thymic involution. The HIV-2 cohort presented elevated sj/β TREC ratios 
as compared to the ones found in HIV-1, suggesting a maintained thymic production for 
prolonged periods of time. In agreement, sj/β TREC ratios showed no significant reduction in 
older as compared to younger HIV-2 infected individuals.  
 
Taken together, these data suggest that in HIV-2 infection, both thymopoiesis and peripheral 
T cell homeostasis are better preserved. Thus, during the course of HIV-2 infection there may 
be an apparent maintenance or possible rebound of thymic function that likely contributes to 
the more benign outcome of the infection. These results support the importance of the thymus 
as a target for immune-based interventions in order to achieve a complete immunologic 
reconstitution under antiretroviral therapy in HIV-1 disease.  
 
The Part II of this work is entitled “TACI Regulation of B cell Differentiation after Antigenic 
Stimulation” and its main objective was to clarify the role of TACI in B cell differentiation. 
TACI deficiency leads to recurrent bacterial infections, particularly of the respiratory tract, 
and impaired responses to vaccination against encapsulated bacteria such as Streptococcus 
pneumoniae or Haemophilus influenzae. The impaired clearance of encapsulated bacteria in 
TACI deficient subjects has been attributed to reduced IgG and IgA production owing to a B 
cell defect. Also TACI deficiencies are associated with CVID in humans. CVID is a primary 
immunodeficiency that comprises a heterogeneous group of diseases with deficient antibody 
production. It is the most prevalent human primary immunodeficiency with clinical 
expression, affecting 1 in 25,000 Caucasians. Recent data showed that 5% to10% of subjects 
with CVID carry at least one germline mutation in the TACI locus. Thus, the second part of 
this work aimed to better understand how TACI promotes antibody production.  
 
In order to clarify the role of TACI in B cell differentiation, TACI KO mice were bred with 
Quasi-Monoclonal (QM) mice that produce robust polysaccharide responses to 4-hydroxy, 3-
nitro-phenylacetic acid (NP)-Ficoll, owing to the high precursor frequency of NP-specific B 
cells in the marginal zone of the spleen, to produce QM TACI KO mice. These mice were 
immunized with NP-Ficoll. The frequencies of antibody secreting B cells were measured by 
ELISPOT and the amount of antibodies produced was quantified by ELISA. It was observed 
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that QM TACI KO mice produce decreased numbers of IgM (2-fold) and IgG (1.6-fold) NP-
specific antibody-secreting cells compared with QM TACI+ mice in response to 
immunization with NP-Ficoll. Moreover, these data indicated that TACI acts at a remote time 
from activation because TACI was shown not to be necessary for activation and proliferation 
of B cells both in vitro and in vivo. Instead, the results showed that QM TACI KO B cells 
remained in the cell cycle longer than QM TACI+ cells and had impaired plasma cell 
differentiation in response to NP-Ficoll.  
 
These data indicated that TACI has dual B cell-autonomous functions, inhibiting prolonged B 
cell proliferation and stimulating plasma cell differentiation, therefore resolving the 
longstanding paradox that TACI may have both B cell-inhibitory and -stimulatory functions. 
By promoting plasma cell differentiation earlier during clonal expansion, TACI may decrease 
the chances of autoantibody production by somatic hypermutation of immunoglobulin genes 
in response to T-independent antigens. 
 
 
Keywords: HIV/AIDS; HIV-2; IL-7/IL7R-α; Thymus; TREC; TACI; T-independent-B-cell 
responses; plasma cell differentiation. 
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PART I  
 
T CELL PRODUCTION IN HIV-2 INFECTION: 
INSIGHTS TO AIDS PATHOGENESIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The more we learn about the world and the deeper our learning, the more conscious, 
specific and articulate will be our knowledge of what we do not know, our knowledge of our 
ignorance” Sir Karl Popper 
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The Human Immunodeficiency Virus type 1 (HIV-1) was first isolated and characterized in 
the early 1980’s, by two independent research teams. This virus, denominated 
lymphadenopathy-associated virus (LAV) by Luc Montagnier and colleagues (1) and termed 
human T-lymphotropic virus type III (HTLV-III) by Robert Gallo and colleagues (2), was 
independently isolated from a lymph node of a patient with lymphadenopathy, and from 
plasma of patients presenting with opportunistic infections or tumors (3-6). The HTLV-
III/LAV virus, later termed HIV-1 (7), was found to be the causative infectious agent of this 
previously unknown acquired immunodeficiency syndrome (AIDS) in 1983 (8-10).   
 
Between 1981, when the first AIDS patients were described, and 2007, approximately 65 
million cases of HIV infection have been diagnosed and 25 million people have died of 
AIDS-related illnesses (11). Moreover, it is estimated that the number of new infections in 
2007 were around 2.5 million cases and that over 5700 people die every day from AIDS 
(depicted in Figure 1). 
 
The hallmark of HIV-1 infection is a profound immunodeficiency, associated with a 
progressive depletion and qualitative defects of the CD4 T cell subset, which in turn leads to 
failure of responses to opportunistic infections, followed by AIDS and death.  
 
Soon after the first AIDS virus was described, Montagnier’s research group described a 
second retrovirus linked to AIDS, subsequently termed HIV type 2 (HIV-2) (12). This new 
virus was isolated from West African patients with AIDS or AIDS-related 
 
symptoms (12, 13) 
and found to be quite common in the West African region (12, 14-17). Nowadays, HIV-2 still 
remains highly confined to West Africa (18), although HIV-2 infected cases can be found in 
certain European countries that have socio-economic ties with this area (19, 20). Portugal 
represents the only non-African country with a significant prevalence of HIV-2 due to 
connections with its ex-colonies. From a total of approximately 30.000 AIDS reported cases 
in Portugal, 3.4% are due to HIV-2 infection (21). In one study, more than 60% of all newly 
diagnosed HIV-2 infections in Portugal could not be directly traced back to a West African 
contact, demonstrating its entrenchment in the local population (22). 
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As described for HIV-1 infected individuals, CD4 T cell counts in HIV-2 infection decline 
progressively, although the disease progression is slower, leading to a limited impact on the 
survival of the majority of infected adults (23, 24). Importantly, viremia is substantially 
reduced in HIV-2 infection (25, 26). Thus, the study of HIV-2 infection offers the possibility 
to reassess the relative importance of virological and immunological parameters in HIV 
pathogenesis, by studying a human immunodeficiency virus that is associated with a 
clinically attenuated infection. The potential of the HIV- 2 model is yet to be fully explored, 
because of the geographic confinement of the infection to West Africa (27-29).  
 
 
 
Figure 1 – Adults and children estimated to be living with AIDS.  
The ranges around the estimates in the table define the boundaries within which the actual numbers 
lay, based on the best available information. Adapted from UNAIDS, AIDS epidemic update 2007 
(11). 
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The Human Immunodeficiency Virus (HIV) 
 
Origins of the virus 
 
Evidence from genome sequencing suggests that HIV-1 and HIV-2 probably crossed the 
interspecies barrier from nonhuman primate species on several occasions (30, 31). The three 
genetic HIV-1 groups – M, N and O – resulted from independent events of cross specie 
transmission most likely from the chimpanzee Pan troglodytes (31-33). Of these events, only 
the M group with its numerous clades or subtypes (A to K) as well as circulating recombinant 
forms gave rise to the AIDS pandemic (34, 35).  
 
Characterization of the HIV-2 virion showed a similar genomic organization to HIV-1, even 
though they only share 40% to 60% of nucleotide homology (36). Interestingly, HIV-2 is 
genetically closer to the Simian Immunodeficiency Virus (SIV), with over 75% nucleotide 
homology (37), a result of interspecies transmissions from the natural host sooty mangabey 
(Cercocebus atys) as illustrated in Figure 2 (27, 35, 38, 39). 
 
SIV infects several nonhuman primates without causing disease or AIDS; such is the case of 
sootey mangabeys or african green monkeys, considered natural hosts for SIVsm or SIVagm, 
respectively (40-42). On the other hand, SIVsm can infect several species of Asian macaques, 
such as the rhesus macaque, causing severe immunodeficiency and AIDS–like syndrome (43, 
44). Thus, the study of SIV infected macaques and comparative analyses of pathogenic and 
non pathogenic SIV infections have constituted important models for the study of HIV 
pathogenesis.  
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Figure 2 – Phylogenetic relationship of primate lentiviruses based on identity of pol gene 
sequences.  
SIVCPZ corresponds to SIV from chimpanzee (Pan troglodytes); SIV L’HOEST from L'Hoest's Monkey 
(Cercopithecus lhoesti); SIVSUN from Sun-tailed Monkey (Cercopithecus solatus); SIVMND from 
Mandrill (Mandrillus sphinx); SIVAGM African Green Monkeys; SIVSYK from Sykes' Monkey 
(Cercopithecus albogularis); SIVMM from Sooty Mangabey (Cercocebus atys). Adapted from Reeves, 
et al (39). 
 
 
 
 
Figure 3 – Representation of the genomic organization of HIV-1 and HIV-2/SIV.   
Adapted from Marlink, R. (27). 
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Replication cycle and latency 
 
HIV-1, HIV-2 and SIV are members of the lentivirus genus included in the Retroviridae 
family, all characterized by the unique enzyme, reverse transcriptase which utilizes the viral 
genomic RNA as a template for synthesis of proviral cDNA (45).  
 
The HIV genome is approximately 10kb, consisting of nine genes flanked by long terminal 
repeat sequences (LTRs) (46), depicted in Figure 3. The HIV-1’s genome, like HIV-2 and all 
other retroviruses, has three major coding regions: gag which encodes for the structural 
proteins of the viral capsid, pol encoding enzymes involved in both viral replication and 
integration and env which encode the viral envelope glycoproteins. The genes gag and pol are 
well conserved in HIV-1, HIV-2, and SIV, and account for most of the cross-reactivity seen 
in enzyme-linked immunosorbent assays (ELISA) for HIV-1 (47, 48). HIV-1 and HIV-2 env 
genes encode for different glycoproteins (gp) that seem to have similar functions during 
infection; the outer membrane gp120 or gp105 and the transmembrane gp41 or gp36, 
respectively in HIV-1 or HIV-2. The LTRs are required for the integration of the viral cDNA 
(provirus) into the host cell genome and subsequent initiation of transcription of the 
integrated provirus (49). HIV-1 and HIV-2 share five additional reading frames tat, rev, nef, 
vif and vpr, coding for the gene products Tat, Rev, Nef, Vif and Vpr, accessory proteins with 
different key regulatory roles during HIV infection. HIV-1 vpu and HIV-2 vpx, although 
similar in sequence encode for proteins, Vpu and Vpx, respectively, that appear to have 
different functions in the infected cell (48). Most of the viral genes have overlapping reading 
frames, which allow the virus to encode several proteins in a small genome, through 
alternative splicing (50). 
 
The virion capsid has a particular cone shape, contained within an external lipid envelope. 
Embedded in this membrane are the transmembrane glycoproteins responsible for binding to 
the host cells, and for fusion of the viral particle with the cell membrane, as illustrated in 
Figure 4A. Two copies of genomic RNA and several viral proteins such as reverse 
transcriptases, proteases and integrases are packaged inside the viral capside (51). 
 
The viral replication cell cycle is schematically represented in Figure 4B. Both HIV-1 and 
HIV-2 enter cells by a membrane fusion process that requires the interaction of their external 
envelope gp with the CD4 molecule and co-receptors from the chemokine receptor family 
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(mainly CCR5 or CXCR4). The first step in cellular infection involves high affinity binding 
of the outer membrane gp to the CD4 molecule of host cells (52). Then, the outer membrane 
gp undergoes a conformational change allowing a better binding to either one of the cellular 
co-receptors (53). The induced conformational shift exposes a transmembrane gp which 
mediates cell-virus fusion. Its fusion domain binds and penetrates the host cell membrane 
bringing the two membranes closer (54), allowing virion content to enter the cytoplasm (55). 
The limited exposure of the key surfaces that mediate virus-host interaction during the 
extracellular stages of the HIV infection is considered a main reason for the failure to 
generate neutralizing antibodies that can control this phase of infection (56, 57).   
 
Once in the cytoplasm, the RNA genome is reverse transcribed into double-stranded DNA by 
the viral reverse transcriptase. This process is highly error prone, leading to mutations of the 
viral genome (49). During the process of trafficking and transport of the viral DNA to the 
nucleus, the double stranded DNA and all viral proteins in the cytoplasm of the host cell 
aggregate, forming preintegration complexes (PICs). At this stage, PICs recruit host cellular 
factors to aid in the cell trafficking to the nucleus (58).  
 
In the nucleus, integration occurs through the interaction of the viral integrase and of host cell 
DNA repair enzymes (59). Furthermore, the sites of HIV integration are not randomly 
distributed in the genome, but occur preferentially in transcriptionally active regions, 
downstream of promoters (60). When the provirus first starts to be transcribed, the messenger 
RNA is fully spliced leading to the production of Tat, Rev and Nef. Tat ensures transcription 
of viral mRNA (59). With the accumulation of Rev in the nucleus mRNA is exported leading 
to the production of the other viral proteins – Env, Vif, Vpr and Vpu or Vpx – and later in 
infection, of Gag and Pol (61). In the cytoplasm, the proteins are assembled to produce the 
viral capsid and envelope. The unspliced mRNA is packaged in the viral particles as well as 
the viral enzymes reverse transcriptase, integrase and protease (62). The completely 
assembled viral particles bud out of the cells, ready to infect other cells. All these processes 
critically depend upon the state of cell activation and cell cycling.   
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(A) 
 
 
 
(B) 
 
 
 
 
Figure 4 – The life cycle of HIV-1.  
(A) Organization of the HIV-1 virion. (B) Schematic description of the events occurring after HIV 
infection of a susceptible target cell.  
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A state of latency is reached when integrated provirus have no active transcription. With the 
development of effective therapies that reduce the plasma viral load by targeting cells that are 
actively replicating virus, the persistence of a latent viral reservoir is considered the most 
important factor precluding the discontinuation of antiretroviral therapy (63-65). The factors 
that determine whether a cell will be latently infected or actively transcribing virus remain 
elusive.  
 
Cell targets: co-receptor usage and tropism 
 
The primary receptor for the HIV-1 particle is the CD4 molecule and, therefore, its main 
targets are CD4 T cells (66) and cells of the monocyte-macrophage lineage (67). Other cells 
have been shown to be infected in vitro though the in vivo relevance is not clear (68). HIV-2 
infection of target cells has also been shown to require CD4 as the primary receptor together 
with one of several chemokine receptors as a co-receptor (69). HIV-2 appears to be more 
flexible in co-receptor usage than HIV-1, that mainly uses CCR5 or CXCR4 (53, 70 , 71, 72). 
Moreover, several HIV-2 strains have been shown to infect certain CD4-negative cell lines, 
generally through the use of CXCR4 or CCR5 alone (73, 74). However, in spite of the 
promiscuity of co-receptor usage exhibited by HIV-2 in vitro, several lines of evidence 
suggest that CCR5 and CXCR4 are as the major co-receptors for HIV-2 infection in vivo (75-
77). 
 
The chemokine receptors, CCR5 and CXCR4, belong to the family of transmembrane 
chemokine receptors.  
CCR5 is upregulated on the surface of effector/memory T cells upon T cell activation and is a 
receptor for CCL3 (macrophage inflammatory protein 1α: MIP-1α), CCL4 (MIP-1β) and 
CCL5 (regulated upon activation, normal T cell expressed and secreted: RANTES). 
Interactions between these molecules regulate homing of effector/memory cells to specific 
lymphoid tissue (78). The importance of CCR5 as an HIV co-receptor, particularly during 
HIV-1 acute infection, became apparent when it was discovered that individuals homozygous 
for a mutation in the CCR5 gene (CCR5∆32) were protected from HIV infection (79). 
CXCR4, the receptor for CXCL12 (stromal derived factor 1: SDF-1), is constitutively 
expressed on CD4 T cells, including naive T cells, and several other cell populations (78). 
These chemokines play diverse roles both during normal lymphocyte development and 
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during inflammation, varying from chemoattractant factors for monocytes and T cells, to 
activators of granulocytes or in homing of hematopoietic stem cell. 
 
Tropism of the HIV particle is currently classified according to its binding to CCR5 (R5-
Tropic) or CXCR4 (X4-Tropic). The R5 variants are associated with the primary infection, 
since they are the predominant phenotype in newly infected individuals. In around 50% of the 
HIV-1 infected patients in advanced disease stage, the viral phenotype switches to an X4 
variant and this change is usually followed by a rapid decline in CD4 T cell numbers and 
progression to AIDS (80). An evolution from CCR5 to CXCR4 co-receptor usage is less clear 
in HIV-2-infected individuals. Many primary isolates have been shown to use a range of co-
receptors including both CCR5 and CXCR4 and only a limited number of X4 viruses have 
been isolated from symptomatic patients (76, 81). In addition, it is not known whether 
primary infection is mainly associated with R5 HIV-2 strains as it has been described in HIV-
1 infection (81, 82).  
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Natural history of HIV-1 infection 
 
HIV-1 is transmitted by contact with infected body fluids, mainly by sexual contact, blood 
transfusion and/or contact with blood products, and by vertical transmission (from mother to 
child during pregnancy, delivery or breast feeding). Despite the multiple modes of 
transmission, there are no obvious differences in disease manifestations in individuals 
infected by different routes. This suggests that even if the initial target cells or route of HIV-1 
infection differ, the subsequent viral spread ultimately results in a similar outcome (83).  
 
Typical course of untreated HIV-1 infection 
 
The acute phase of HIV-1 infection is characterized by viral dissemination throughout the 
lymphoid tissue. The highest levels of viremia are typically achieved during the acute 
infection. A selective depletion of memory CD4 T cells occurs coincidently with the active 
viral replication. Following exposure, around 50% of individuals experience an acute phase 
syndrome that may persist for up to several weeks, with symptoms ranging from a mild cold 
to a flu-like or mononucleosis-like disease. At the end of the acute stage, viremia decreases, 
mainly as a result of the expansion of HIV-1 specific CD8 T cells (84), but also due to the 
response of other components of the immune system, such as specific antibodies. 
Concomitantly, the CD4 T cell counts increase, although to values usually below the pre-
infection levels. The parallel expansion of CD8 T cells, that is only partially due to HIV 
specific responses, causes an inversion of the CD4:CD8 ratio, which persists throughout the 
infection. The viral set point, attained through a balance between the viral replication and the 
host immune response, is predictive of the rate of progression to AIDS in untreated 
individuals (85), such that the higher the viral set point, the faster the disease progresses (86). 
 
Recent studies have provided evidence for the role of the infection of gut-associated 
lymphoid tissue (GALT) in the profound CD4 depletion during acute infection. In the gut of 
acutely HIV-1-infected individuals a massive mucosal CD4 T cell depletion is observed, 4–6 
weeks post-infection, much more marked than the decrease in CD4 T cell counts in the 
peripheral blood (87). It is important to note that the majority of CD4 memory T cells in 
uninfected humans resides in the GALT (more than 95%), with the remaining cells 
distributed by the blood (less than 2%), spleen, peripheral lymph nodes and other lymphoid 
tissues. As a consequence, CD4 memory T cell depletion is more rapid and profound in the 
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GALT during HIV-1 primary infection (88). Although this depletion is observed both in 
pathogenic and non pathogenic SIV infection (89, 90), the extent of this initial depletion has 
been suggested to determine the outcome of the HIV-1 infection. 
 
 
                    ~ 12 Weeks     8-10 Years     2-3 Years   
 
 
Figure 5 – Typical course of untreated HIV-1 infection. 
 
 
Following resolution of the acute stage, a chronic persistent infection is established, that is 
associated with an asymptomatic period of clinical latency, prior to advanced 
immunodeficiency or AIDS. Numerous defects in immune function are evident in this phase 
of HIV-1 disease prior to substantial CD4 T cell loss (86). Despite the lack of clinical 
symptoms, ongoing virus replication can be detected consistently in lymphoid tissue attested 
by the usually significant levels of viremia. In vitro tests have shown that cell-mediated 
immune responses are progressively lost, first to microbial recall antigens, then to the more 
potent stimulation by alloantigens, and finally to mitogens. These in vitro functional T cell 
defects are also reflected in vivo by the loss of delayed type hypersensitivity skin testing (91).  
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Thus, despite a potent immune response and the marked downregulation of virus replication 
during the acute phase, HIV-1 succeeds in establishing a state of chronic infection with a 
variable degree of persistent viral replication. 
 
The final stage of disease progression is characterized by an increased risk of opportunistic 
infections and tumors – AIDS, leading to death in 2 to 3 years in the absence of antiretroviral 
therapy (ART). Complex interactions between variable host responses and a highly variable 
pathogen determine the rate of the deterioration of the immune system. The median period 
from infection to AIDS is estimated to be 8-10 years, but AIDS can occur in months in the so 
called rapid progressors, whereas other infected individuals have remained asymptomatic for 
more than 10 years with relatively well preserved CD4 T cell counts, which are named long 
term non-progressors (91). A number of severe clinical manifestations, associated with 
reduced cell-mediated immunity in HIV-1 infected patients, are included in the Centers for 
Disease Control and Prevention (CDC) definition of AIDS. The AIDS-defining criteria also 
include a low CD4 T cell count (less than 200 CD4 T cells/µL blood). Since progression of 
HIV-1 disease is usually directly associated with a decrease in CD4 
 
T cell counts and an 
increase in plasma HIV-1 viral load, measurement of these surrogate markers of infection has 
been used as a tool for assessing disease stage, prognosis and monitoring therapeutic response 
(86).  
Antiretroviral therapy 
 
Antiretroviral therapy or ART, using combinations of three or more drugs, is also termed 
highly active antiretroviral therapy in agreement with its major impact on slowing the 
progression of disease in a substantial proportion of adequately treated patients, by 
controlling viremia and allowing CD4 T cell counts to rise. It is the most important 
achievement in the battle against HIV-1 infection so far, with impressive impact on morbidity 
and mortality (92). Recent data from a comparative study of mortality before and after the 
introduction of ART in HIV-1 cohorts in Norway show that in the ART era the mortality was 
reduced by 80% (93). In another study, Walensky et al (94) demonstrated that since 1989, at 
least 3 million years of life have been saved in the United States as a direct result of ART.  
 
 
 49 
 
Part I - Introduction 
 
Reservoirs 
 
The number of available antiretroviral drugs has increased rapidly in the last decade, allowing 
for the use of several effective combinations of 3 or more drugs. However, strong evidence of 
the inability of ART to eradicate HIV-1 infection has come from studies of individuals who 
began antiretroviral therapy during the chronic stage of HIV-1 infection, showing that 
interruption of effective long-term antiretroviral therapy resulted in a rapid rebound of plasma 
viremia in almost all individuals (95, 96). Moreover, individuals whose ART was interrupted 
and remained off therapy for 4 to 6 weeks, experienced increases in the plasma HIV-1 RNA, 
to the same levels reached prior to the initiation of ART (97). These data suggest that ART 
does not eradicate HIV-1 infection and has no effect upon the post-therapy replication 
kinetics of the virus. HIV-1 proviral DNA and mRNA can be detected in CD4 T cells in 
individuals who have maintained "undetectable" plasma viremia (<50 copies of HIV-1 
RNA/ml) for prolonged periods of time while receiving ART. Thus, viral reservoirs and some 
ongoing HIV-1 replication persist in the presence of effective antiretroviral therapy and it is 
currently consensual that complementary immune-based therapies will be required to 
eradicate or control the viral reservoirs.  
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HIV Immunopathogenesis 
 
The hallmark of HIV infection is the progressive CD4 T cell depletion associated with active 
viral replication. There is considerable controversy regarding the relative contribution of the 
various putative mechanisms to the depletion of CD4 
 
T cells during the course of HIV 
infection.  
Tap and drain hypothesis 
 
In 1995, Ho and colleagues (98) proposed that the virus was the major driving force behind 
the CD4 depletion, whether it was by direct infection and concomitant cytolytic effects, or by 
the removal of the infected cells by the immune response. This was termed the “tap and 
drain” hypothesis. In this analogy a sink represented the CD4 T cell compartment, an 
unplugged drain depicted the impact of HIV infection on CD4 numbers and water flowing 
from an open tap symbolized the production of new CD4 T cells. Over time the open tap, i.e., 
the production of new CD4 T cells would be unable to counteract the “flow of water going 
down the drain”, ultimately resulting in the depletion of the CD4 compartment. The major 
evidence that supported this hypothesis came from the study of the reduction of viremia and 
increase in CD4 T cells in the blood after treatment with a protease inhibitor (98, 99). 
Mathematical modeling applied to these data estimated that everyday there was a destruction 
of 2x109
 
 lymphocytes by the virus, which was compensated by the regenerative capacity of 
the immune system in the steady state (98-100). In this model, the ability to produce new 
cells progressively deteriorates resulting in AIDS. This mathematical model predicted that the 
half-life of the infected CD4 T cells was such that in 10 years the CD4 compartment would 
be empty and also that continuous therapy use would be able to eradicate infection in less 
than 2 years (98-100).  
One of the first observations that directly challenged this simplistic view was that the initial 
rise in CD4 T cells did not signify the production of new cells as predicted. In fact, the 
increase in CD4 T cell counts that occurred immediately after initiation of therapy was 
subsequently shown to result mainly from the redistribution of CD4 T cells into the blood 
stream, that were trapped in the lymph nodes and other tissues, due to decrease in antigen 
load (101, 102). Also, the frequency of infected CD4 T cells was not sufficient to explain the 
CD4 T cell depletion by direct virus killing (103). Moreover, the major CD4 depletion could 
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not be explained in such a way, as the virus preferentially infects activated T cells and these 
cells are expected to die as a result of activation induced cell death (AICD) during the 
contraction of the immune response, as stressed by Grossman et al (104-106). 
 
Chronic hyper immune activation 
 
Studies on non pathogenic SIV infection, such as SIV infection of sootey mangabeys 
(SIVsm), showed that, despite the presence of very high viral load, there was no chronic 
depletion of CD4 T cells (107). On the other hand, when a susceptible species like rhesus 
monkeys were infected with SIVsm, there was a major CD4 depletion that correlated with 
viral load. This depletion was also correlated with an upregulation in activation markers, not 
found in SIV infected sootey mangabeys, where only a transient or no upregulation of 
activation markers was found (108, 109). 
 
These observations support the proposition of a new paradigm of HIV pathogenesis, where 
the driving force behind CD4 depletion is chronic hyper-immune activation. Several other 
lines of evidence sustain a major role of chronic activation on AIDS progression. Liu et al 
(110) showed that increased expression of the activation marker CD38 on T cells positively 
correlated with poor disease prognosis. Additionally, a high level of apoptosis associated with 
bystander activation was documented in non-infected cells including CD8 T cells (111) that 
was shown to contribute to the disruption of the immune system. This chronic activation was 
characterized by increased, sustained frequencies of lymphocytes expressing activation 
markers, not only CD38, but also others like HLA-DR, and an increased frequency of cycling 
cells as assessed by Ki-67 (112, 113). In fact some of the first markers of disease progression 
to be used, before viral quantification, were β2-microglobulin and neopterin, which are 
markers indicative of immune activation. Moreover, data from our laboratory further support 
a role of immune activation in AIDS pathogenesis. Sousa et al (112) showed that CD4 
depletion is directly linked to immune activation both in HIV-2 and HIV-1 infection and only 
indirectly to viral load (106, 112). 
 
Chronic hyper activation has a major impact on immune function through many mechanisms: 
inducing functional cellular impairment; damaging the local lymphoid tissue architecture; 
altering cell trafficking; promoting selective depletion of resting naive and memory CD4 and 
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CD8 T cells. Moreover, even though quiescent CD4 T cells can be infected with HIV, reverse 
transcription, integration, and virus spread are much more efficient in activated cells (114). In 
addition, it has been demonstrated that cellular activation induces expression of virus in 
latently infected CD4 T cells (115). 
 
An increase in microbial translocation associated with the perturbations of the gut mucosa 
documented in HIV and SIV infections as been suggested as one of the possible contributing 
factors to the pan-immune activation (87, 116). The increase of bacterial products such as 
LPS in the blood would contribute to maintain monocyte/macrophage, dendritic cells and B 
cells in a continuous state of activation.  
 
Currently, HIV disease progression is thought to result from a multifactorial process, mainly 
driven by persistent immune activation induced by antigens and inflammatory factors, 
modulated both by viral determinants and host genetics factors. 
 
Ability to counteract CD4 depletion 
 
Regardless of the mechanisms involved in the CD4 depletion, the ability to replenish the T 
cell pool is a major determinant of disease progression. 
HIV-associated chronic immune activation results in constant recruitment of CD4 T cells 
from the naive into the memory-effector activated pool. This creates a constant pressure on 
the replenishment mechanisms of the CD4 populations. Maintenance of the naive T cell pool 
is currently thought to be due to mechanisms of homeostatic control of post-thymic T cells as 
well as of an age-dependent contribution of thymic emigrants (117). Thus direct or indirect 
impact of HIV on either de novo T cell production, or thymus independent homeostatic 
mechanisms, can further influence the course of HIV infection. The ability to counteract CD4 
depletion during HIV-1 and HIV-2 infection represent the focus of this work. 
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T cell production in HIV disease: relative contributions of thymic output and peripheral 
T cell homeostasis  
 
Peripheral T cell proliferation and IL-7 as a critical homeostatic cytokine   
 
Homeostasis is a state of equilibrium attained when a given population has similar gains and 
losses of its components. When in a steady state, the peripheral pools of naive and memory T 
cell populations occupy their space in the lymph nodes and all other sub-compartments of the 
immune system, circulating between them, occasionally dividing or dying.  
 
Homeostatic mechanisms and their modulators may be different for different sub-populations 
of lymphocytes. Both the CD4 and CD8 naive and memory T cell pools are confined to 
different locations; require different stimuli to survive and to perform their function; and 
likely obey different “sets of rules” for the maintenance of their numbers. Although these 
rules remain largely unclear, in steady state conditions, memory T cells are thought to 
compete for survival signals with other memory T cells but not with naive T cells (118, 119), 
thus occupying different “niches” (120). Increasing evidence suggests that the homeostasis in 
these different niches is regulated through competition for limiting resources. Naive T cells 
have been shown to require continuous contact with self-peptide bound to the major 
histocompatibility complex (MHC) molecule and/or cytokines such as interleukin (IL)-7. 
Memory CD8 T cell survival is controlled mostly by IL-7 that provides a survival signal and 
IL-15 that is thought to mediate proliferation (121). The factors that control memory CD4 T 
cells turnover and survival are less clear. Although a significant part of these studies have 
been performed in mouse models, it is thought that similar mechanisms apply to human’s T 
cell homeostasis.  
 
IL-7 is considered a key cytokine in T cell homeostasis acting both during thymopoiesis and 
in the periphery, where it promotes T cell proliferation and survival, particularly of the naive 
pool (122-124). IL-7 is constitutively produced by stromal cells of the bone marrow, thymus, 
mucosal lymphoid tissues, and lymph nodes (125-128). 
 
The potential of IL-7 to restore immune competence through the combined effects of 
increased thymic output (129) and enhanced peripheral homeostatic expansion of T cells 
(130, 131), highlights this cytokine as a potent modulator of T cell immune reconstitution 
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(132). The IL-7 receptor is composed of a α chain and a common γ chain, shared with a 
family of cytokines, namely IL-2, -4, -9, -15 and -21. The expression of the IL-7Rα 
(CD127) has a critical role in the regulation of the IL-7 biology (133, 134). IL-7 signaling 
results in a transient down-regulation of the IL-7Rα that is thought to allow adequate sharing 
of available IL-7 by a large number of T cells (135). 
 
 
 
Figure 6 – Schematic representation of changes in IL-7Rα expression during post-thymic T cell 
development.  
Recent thymic emigrants (RTE) display high levels of IL-7Rα and are highly responsive to IL-7. 
Although the expression of IL-7Rα is diminished transiently following the activation of T cells, both 
CD4 and CD8 naive and memory T cells express IL-7Rα. Adapted from Snyder, et al (136). 
 
 
In lymphopenic states, such as those found following radiotherapy or chemotherapy, or in 
some acute viral infections, such as measles, homeostatic mechanisms ensure the 
replenishment of T numbers (137-139). Thus these homeostatic mechanisms play a pivotal 
role in assuring that the depleted T cells populations are replaced.  
 
Circulating IL-7 levels increase in lymphopenic states, either due to increased production 
resulting from a compensatory feedback loop, or increased availability due to the reduction of 
cell targets (128, 131). Furthermore, clinical studies have reported an increase in circulating 
levels of IL-7 in the settings of HIV-1 induced T cell depletion, idiopathic CD4 lymphopenia 
and following cancer chemotherapy, which returned to normal levels upon recovery of the T 
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cell populations (128, 131). Thus, the clarification of the role of the IL-7 network in the 
maintenance of the T cell pool is of major importance.   
 
T cell production in the thymus  
 
The thymus is the central lymphoid organ where T lymphocytes develop and mature. It is 
therefore essential in the establishment of the peripheral T cell pool and the in the generation 
of a diverse T cell receptor (TCR) repertoire. TCR gene rearrangement plays a pivotal role in 
thymocyte assembly of a functional TCR and at the same time ensures that T cells have 
different specificities. In order for this to occur, receptor assembly proceeds in stages, each 
stage being verified for correct assembly. Developing thymocytes undergo a series of distinct 
phases, marked by changes in the rearrangement status of their TCR genes that are associated 
with varied levels of expression of cell surface proteins, such as TCR, CD3 complex, CD4 
and CD8. These surface changes reflect the state of functional maturation of the cell. Thus, 
particular combinations of cell-surface proteins can be used as markers for thymocytes at 
different stages of differentiation. Early in T cell development, cells commit to two main 
distinct lineages: αβ and γδ. Later, αβ T cells develop into distinct functional subsets: CD4 
and CD8 T cells (140).  
 
The earliest lymphoid progenitors, termed common lymphoid precursors (CLP) are derived 
from bone marrow hematopoietic stem cells. Interactions with the thymic stroma trigger an 
initial phase of differentiation along the T cell lineage pathway followed by cell proliferation 
and the expression of the first cell-surface molecules specific for T cells. At this stage the 
thymocytes bear distinct markers of T cell lineage, but still lack the CD3-TCR complex and 
CD4 or CD8, being termed double-negative (DN) thymocytes.  
During the DN phase, rearrangement of the TCR genes occurs. The genes that encode the 
variable regions of the TCR α, β, γ, and δ chains are assembled through recombination of 
their multiple variable (V), and joining (J) gene segments. In addition the TCRβ and TCRδ 
loci have diversity (D) segments as well as V and J segments to be rearranged. The TCRδ 
locus is embedded within the TCRα locus in such a way that any V-Jα rearrangement 
automatically deletes the TCRδ locus entirely (140). The particular pathway that the cells 
follow depends on whether they successfully rearrange D-Jβ and V-D-Jβ, generating a 
productive TCRβ open-reading frame before they have completed productive rearrangements 
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of both the γ and δ loci. In the first case, they develop into αβ T cells; in the second case, 
they develop into γδ T cells.  
 
 
 
 
 
 
Figure 7 - TCR α and β chains gene rearrangement.  
Representation of the rearrangement of the TCR α and β chains and also of the episomal DNA circles 
generated during excisional rearrangement of TCR genes, T cell receptor excision circles (TREC). 
Adapted from Paul et al (140) and Janeway et al (141). 
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The rearranged TCRβ then dimerises with a pre-T-α chain, forming the pre-TCR that is co-
expressed on the cell surface. Productive assembly results in the arrest of further β 
rearrangement, leading to cell proliferation and subsequently expression of CD4 and CD8 
that defines the double-positive (DP) stage.  
The TCRα rearrangements occur mostly during the DP stage, following multiple rounds of 
proliferation. A complete TCR is then presented on the surface of the DP cell, complexed 
with the CD3 molecules. Thymocytes are subsequently tested for TCR functionality and self-
MHC interaction, under extremely stringent conditions, with only a small proportion of cells 
surviving. These processes are necessary to determine whether the newly expressed TCRαβ 
has sufficient affinity for MHC molecules to survive. On the other hand, thymocytes that 
have strong interactions with self-antigens in the thymus are deleted in order to prevent 
autoimmunity. Also during this process the TCR-MHC interactions, guide or select cells to 
develop into the two main αβ T cell subsets. Cells with a TCR that recognize MHC class II 
molecules develop as CD4+ cells, whereas those with TCR that recognize MHC class I 
molecules develop as CD8+
 
 cells by mechanisms that are not yet fully clarified. Single 
positive CD4 or CD8 αβ T cells leave the thymus and are incorporated into the peripheral 
naive T cell pool (140).  
Direct HIV impairment of the thymus  
 
Evidence that suggests that HIV can impair or reduce thymic function has been accumulating. 
Thymic structure assessed in postmortem analysis of AIDS infected patients shows severe 
destruction of architecture and reduced thymocyte numbers. HIV-1 infection of the thymus in 
vivo has been confirmed (142-144) as a consequence of the thymocyte expression of the 
primary HIV-1 co-receptors, CXCR4 and CCR5. It has been shown that both R5 and X4 
tropic viruses can enter and complete reverse transcription in most thymocyte subsets (145, 
146). Also, Sopper et al (147) showed that CD4 thymocytes decrease during chronic stage of 
SIVsm infection in the rhesus macaque model. However, in a small clinical study on HIV-1 
patients that had been thymectomized prior to infection, it was shown that there was no 
significant alteration in disease progression in comparison to the non-thymectomized HIV-1 
infected control cohort (148). Also in juvenile rhesus macaques thymectomies had apparently 
little impact on naive T cell production (149). Given these data, the impact of a functional 
thymus on HIV progression is an important subject to study. The ability to assess thymic 
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function or lack thereof, which may be evaluated by measuring thymic output (i.e. the 
number of T cells exiting the thymus per day), is essential to understanding the impact of 
alterations to this process on the correct functioning of the immune system during a persistent 
chronic infection like HIV. For that purpose the identification of markers that define recent 
thymic emigrants (RTE) is of major importance and substantial technical efforts have been 
devoted to identifying such a phenotype. 
 
Markers of thymic function upon HIV infection 
 
Indirect methods have been used to evaluate thymic function, which include determination of 
naive T cell subsets and naive/memory imbalances. The simultaneous expression of CD45RA 
and CD62L on the surface of CD4 T cells is currently thought to identify the majority of the 
naive population, while for CD8 T cells the simultaneous surface expression of CCR7, 
CD45RA and CD27 is considered a naive phenotype (112). However, in the setting of HIV 
infection, the persistently increased flow of T cells from the naive to the memory 
compartment makes these analyses difficult.  
 
Computer tomography scans of the chest have been used to correlate the thymic sizes of 
HIV-1 infected individuals with their CD4 naive (CD45RA+CD62L+
 
) lymphocyte counts, but 
such an imaging technique cannot reliably measure the true lymphoid mass of the thymus 
because of the difficulty to accurately discriminate thymic from adipose tissue (150).   
The detection of the episomal DNA circles generated during excisional rearrangement of 
TCR genes, was postulated to be a reliable measurement for RTE status. These episomal 
DNA circles, termed T cell receptor excision circles (TREC) are the “by-products” of TCR 
gene rearrangement events that occur during thymopoiesis (depicted in Figure 7B). (151-
156). Since TREC are not regenerated upon subsequent division of TREC-containing cells, 
their numbers are diluted-out upon cellular proliferation (155-158). Thus, the detection and 
quantification of TREC in peripheral T cells serves as a marker for the recent thymic 
emigrant population (152). In this case though, “recent” denotes naive T cells that have 
undergone no more than a few cellular divisions since leaving the site of TCR rearrangement 
and does not necessarily reflect the time elapsed since the rearrangement event (159). 
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As the TCRα chain loci are the last to undergo rearrangement, the excised DNA containing 
the δ loci, termed sjTREC, was primarily used by Douek et al (155) as a marker for RTE to 
study thymic function in HIV infected patients. As expected, in a group of healthy controls, 
decreasing numbers of sjTREC were observed with aging reflecting a gradual loss of thymic 
function, although it was maintained until old age. Interestingly, it was also reported that 
sjTREC were reduced in HIV-1 infected individuals and increased following treatment with 
ART, which suggested impairment of thymic function during HIV-1 infection. However, in 
view of the consequences of the generalized chronic immune activation reported during HIV-
1 infection, the rapid decline in sjTREC could simply be due to changes in peripheral T cell 
division rates. Thus, TREC may be lost by increased cell division in the periphery and not by 
a diminished thymic output (157, 160). 
 
Importantly, Dion et al (161) proposed a marker for measuring thymic function, based on 
quantification of TREC molecules generated during both TCRβ and TCRα chain loci 
rearrangement events. Thus, the βΤREC, resultant from the TCRβ gene rearrangements, are 
quantified in addition to the sjTREC (156) and then a sj/β TREC ratio is calculated (162, 
163). This ratio is independent of peripheral T cell proliferation and death rate in the 
periphery.  Thus, the sj/β TREC ratio directly reflects the number of proliferative cycles 
undergone by precursor T cells during their intrathymic differentiation, which has been 
shown to directly correlate with thymic output. Therefore, the quantification of the βTREC, 
the sjTREC and the sj/β TREC ratio provides a more accurate measure of thymic function, as 
illustrated in Figure 8 (161). Results generated using this technique show suppression of 
intrathymic proliferation in HIV-1 infected patients in the initial phase of disease (161). 
Moreover, it was recently demonstrated the slow progression of  HIV-1 disease and the 
maintenance of circulating CD4 T cells are strongly associated with efficient thymopoiesis 
(162).  
 
 
 
 
 
 
 60 
 
Part I - Introduction 
 
 
Figure 8 – Schematic representation of the effect of intrathymic proliferation on βTREC and 
sjTREC numbers. 
TN: Triple Negative stage; DN: Double Positive stage; SP/RTE: Single Positive/ Recent Thymic 
Emigrant stage. Adapted from Dion, et al (161). 
 
 
T cell surface markers that clearly identify an RTE subpopulation and can be quantified by 
techniques such as flow cytometry, exist for some species, such as chicken (chT1) (152) and 
rat (Thy-1, RT6) (164), but no equivalent marker has been identified in human T cells. 
Kimmig et al (165) proposed CD31 as a surface marker for cells that recently left the thymus, 
based on the observations that the subdivision of naive CD45RA+ T cells according to CD31 
expression has an impact on the amount of TREC quantified, since the CD31+CD45RA+ T 
cell subpopulation has an enrichment in TREC and the subset of naive CD31– CD45RA+
 
 T 
cells has lower TREC levels (165). 
Each of these measurements has its advantages and disadvantages, therefore, combinations of 
these parameters can provide a picture of the contribution of thymic output and peripheral 
homeostatic expansion to maintenance of T cell populations.  
 
Impact of HIV-1 on the maintenance of the CD4 T cell pool  
 
In order to study the impact of HIV-1 on the mechanisms of the naive CD4 T cell pool 
replenishment, it is of major importance to clarify the role of the IL-7 network as a peripheral 
homeostatic factor and also to address the role of maintenance of thymic output in disease 
progression. The present work took advantage of the study of an attenuated model of HIV 
disease, the second human immunodeficiency virus, HIV-2.  
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Models to study HIV-1 infection 
 
Understanding the host immune and viral factors that contribute to protection from infection 
or disease progression remains elusive, despite years of research on HIV-1. 
 
A common strategy to investigate HIV immunopathogenesis has been to use natural models 
of HIV-1 infection with unusual clinical outcomes, such as the so called long-term non-
progressors (LTNP). LTNP are usually considered to be those individuals who have been 
infected with HIV for a long period (e.g. more than10 years), with CD4 T cell counts in the 
normal range that remain stable over time, in the absence of ART, irrespective of their 
viremia (166). More recently, much effort has also been put into the study of the rare 
individuals that maintain plasma viral RNA at <50 copies per milliliter without ART. These 
“Elite controllers” are estimated to represent less than 0.1% of all HIV-1 infected patients. 
When these more stringent definitions based predominantly on levels of plasma viremia are 
applied, very strong genetic associations with HLA B*5701 and HLA B*2705 alleles have 
been found (167, 168). Despite this, these groups have been shown to be heterogeneous. 
Many different factors have been implicated such as variability in individuals’ genetics, 
immune response to the virus and/or the possibility of infection with attenuated strains of 
HIV. Thus, the study of LTNP/Elite controllers is very restricted to the small number of 
individuals that can be adequately paired in each study cohort. 
 
Other approaches to study the immunopathogenesis of HIV have been provided through the 
study of non-human primate models of infection (169) and numerous insights related to 
disease progression have come from studies of pathogenic and nonpathogenic SIV infections 
(170). In their natural hosts, SIV infections cause no disease, whereas SIV infection in 
susceptible monkeys causes severe immunodeficiency and an AIDS-like syndrome (171). 
Thus, these are two comparable models of infection with different outcomes, even though 
extrapolation of nonhuman primate models to human HIV has many limitations, for instance 
the different species’ life-spans and the time of progression to AIDS (2 years vs 10 years on 
average, respectively).  
 
There are no other animal models to address AIDS pathogenesis and although lots of 
expectation has surrounded the humanized mice model, there are still significant limitations 
in the investigation of T cell homeostasis (172).  
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HIV-2 as a model of attenuated disease  
 
HIV-2 is an AIDS causing retrovirus apparently able to generate the same clinical spectrum 
as HIV-1. However, in HIV-2 infection viremia is much reduced, in most cases undetectable, 
and the rate of CD4 T cell depletion is much slower than in HIV-1 infected patients. 
Therefore, as initially stated, HIV-2 infection is considered an attenuated form of HIV 
disease and a very important model for the study of basic pathogenic mechanisms in 
HIV/AIDS and the identification of new targets for therapeutic interventions.  
 
HIV-2 infected individuals have very low to undetectable viremia 
 
As already mentioned, during the course of HIV-2 infection, the levels of virus in circulation 
are usually undetectable. At first, it was thought that the aviremia in individuals infected with 
HIV-2 was due to the use of viral quantification techniques that were developed for the 
quantification of HIV-1 viral load. But the development of PCR-based techniques to quantify 
the HIV-2 RNA copies in plasma confirmed that the level of viremia in all stages of infection 
is much lower than in HIV-1 and, that in most cases, it is below the limit of detection (25, 
173), a finding that had been predicted by the reduced frequency of successful virus isolation 
from HIV-2 infected patients (174). Interestingly, the quantitative assessment of HIV-2 
provirus load documented levels similar to those observed in HIV-1 infected individuals 
(175, 176). The levels of HIV-2 cell-associated proviral load suggest that the virus is able to 
disseminate and establish viral reservoirs as efficiently as HIV-1. 
 
As a consequence of the very low to undetectable viral load, the likelihood of HIV-2 
transmission is much lower than that for HIV-1 infection (20, 23). Reduced vertical 
transmission rates of 0 to 4% of HIV-2-positive pregnancies (26, 177, 178) which is quite 
distinct from the vertical transmission rates of 33% of in HIV-1-positive pregnancies, in the 
absence of antiviral therapy (178-180). Also, HIV-2 appears to be less readily transmitted by 
sexual contact (26) and the efficiency of heterosexual transmission of HIV-2 is estimated to 
be five times lower than that of HIV-1 (181, 182). Interestingly, the prevalence rates of HIV-
2 infection increases among older men and women (23, 183, 184), suggesting that HIV-2 has 
been present in West Africa for several generations. The lower sexual transmission rate of 
HIV-2 compared with HIV-l may help explain the reason for the more confined geographical 
distribution of HIV-2, whereas HIV-l has spread worldwide (18).  
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Decline in CD4 T cell counts during progression of HIV-2 disease 
 
In HIV-2 infected individuals, CD4 T cell counts decline progressively, as in HIV-1 
infection, but the rate of CD4 T cell decline is slower with a longer asymptomatic period and 
a limited impact on the survival of the majority of infected adults (24, 185, 186). In a recent 
longitudinal study in French cohorts by Drylewicz et al (187), the rate of CD4 T cell decline 
was calculated for both infections. In HIV-1 infection, CD4 T cell counts declined at a rate of 
49 cells/µl per yr, whereas in HIV-2 infection this rate was only 9 cells/µl per yr. 
Despite this, it is very important to note that in cross-sectional studies of immunologic 
parameters it is possible to pair HIV-1 and HIV-2 patients at a similar disease stage with the 
same CD4 T cell counts, which is not possible in other clinical models of HIV pathogenesis, 
like LTNP. These types of comparisons allow the impact of CD4 depletion per se, on the 
parameters under evaluation to be taken into account. 
 
Comparable chronic immune activation during HIV-2 and HIV-1 infections 
 
As previously mentioned the pathogenic effects of HIV-1 have been linked to a state of 
severe immune activation and most likely are not solely dependent upon direct infection and 
viral killing. Thus it was hypothesized that one possible reason for the less detrimental effect 
of HIV-2 infection on the host could be due to a lack of generalized immune activation. 
However, Sousa et al in 2002 (112) reported that HIV-1 and HIV-2 patients with a similar 
degree of CD4 depletion displayed similar levels of T cell hyper-immune activation and 
similar numbers of cycling cells in the peripheral blood despite large differences in the 
plasma viral load. HIV-1 and HIV-2 infected patients were grouped according to levels of 
CD4 depletion and it was observed that with this categorization, the two infections exhibited 
a similar spectrum of immune perturbations: imbalances in the naive/memory-effector 
population ratios; comparable upregulation of CD4 and CD8 T cell activation markers (HLA-
DR, CD38, CD69, Fas molecule); a similar increase in the frequency of cycling CD4 T cells 
(Ki67+), which was in strong correlation with the expression of activation markers; and a 
similar level of anergy, as assessed by the in vitro proliferative responses to CD3 stimulation 
and to a panel of microbial antigens. Thus, for the same level of CD4 T cell depletion, HIV-1 
and HIV-2 infected patients exhibited similar elevations in the frequencies of activated and 
cycling T cells. 
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Study of factors that determine CD4 T cell replenishment in HIV-2 infection 
 
However, despite the same levels of activation at a given degree of CD4 depletion, HIV-2 
patients are known to progress to AIDS more slowly, suggesting an increased ability to 
counteract the CD4 loss associated with immune activation. It is thus plausible that the 
mechanisms of CD4 T cell replenishment are better maintained in HIV-2 than in HIV-1 
infection, and that this may be a decisive contributing factor to the slower rate of CD4 T cell 
depletion in HIV-2 infection.  
 
The main advantage in using this clinically attenuated model of infection is that it is possible 
to study the differences in mechanisms of naive CD4 T cell pool replenishment in HIV-2 and 
HIV-1 infection, in cohorts of patients that are paired for age and disease stage. The final goal 
is to provide insights into the mechanisms of replenishment of the CD4 T cell pool, which is 
fundamental in understanding the pathogenesis of HIV infection. 
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Aim  
 
The main objective of this work was to contribute to the understanding of the relative 
importance of factors involved in HIV/AIDS immunopathogenesis, specifically focused on 
those related to the replenishment of the naive CD4 T cell pool through peripheral 
homeostatic mechanisms and/or thymopoiesis. HIV-2 infection was used as a model of 
attenuated HIV disease. In comparison with HIV-1 infection, HIV-2 is characterized by a 
much slower progressive CD4 T cell decline, although with similar levels of hyperimmune 
activation for the same degree of CD4 depletion, despite the reduced viremia. 
 
Firstly this work aimed to clarify the role of IL-7 network in the maintenance of the T cell 
pool by comparing HIV-1 and HIV-2 infections. IL-7 is a non-redundant cytokine for T cell 
homeostasis that acts in the periphery promoting proliferation and survival of naive and 
memory-effector T cell pools. HIV-1 infection is associated with an increase of circulating 
IL-7 levels, in direct correlation with the decrease in CD4 T cells, and is also associated with 
a decreased expression of IL-7Rα on T cells. Circulating levels of IL-7 were quantified in 
serum of HIV-2 and HIV-1 infected patients stratified according to CD4 T cell depletion. 
Also, longitudinal studies of circulating IL-7, in parallel with CD4 T cell counts, were 
performed in HIV-2 patients to further characterize the relationship between increasing IL-7 
and decreasing CD4 T cell numbers. Quantification of IL-7Rα (CD127) was performed using 
flow cytometry in parallel with markers of naive and effector-memory CD4 and CD8 T cell 
subpopulations in HIV-2 and HIV-1 infected patients.  
 
Secondly, the contribution of thymic output to disease progression rate was addressed. To 
study alterations in thymic function, Dion et al (161) recently developed methodologies that 
allow the quantification of excision circles resulting from different intrathymic TCR gene 
rearrangement (TREC), sj and βTREC and the calculation of a sj/β TREC ratio (162, 163). 
This marker, which is independent of peripheral T cell proliferation and death rate, directly 
reflects the number of proliferative cycles undergone by precursor T cells during their 
intrathymic differentiation, thereby providing a more accurate measure of thymic function 
(161). Thus, a collaboration with Dr. Cheynier’s group was established to study sj and 
βTREC in PBMCs of HIV-2 and HIV-1 infected patients in order to evaluate sj/β TREC ratio 
relationship with the rate of CD4 T cell decline.  
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Abstract  
 
IL-7 is a non-redundant cytokine for T cell homeostasis. Circulating IL-7 levels increase in 
lymphopenic clinical settings, including HIV-1 infection. HIV-2 infection is considered a 
“natural” model of attenuated HIV disease given its much slower rate of CD4 decline than 
HIV-1 and limited impact on the survival of the majority of infected adults. We compared 
untreated HIV-1 and HIV-2 infected patients and found that the HIV-2 cohort demonstrated a 
delayed increase in IL-7 levels during the progressive depletion of circulating CD4 T-cells as 
well as a dissociation between the acquisition of markers of T-cell effector differentiation and 
the loss of IL-7Rα expression. This comparison of two persistent infections associated with 
progressive CD4 depletion and immune-activation demonstrates that a better prognosis is not 
necessarily associated with higher levels of IL-7. Moreover, the delayed increase in IL-7 
coupled with sustained expression of IL-7Rα suggests a maximization of available resources 
in HIV-2. The observation that increased IL-7 levels early in HIV-1 infection were unable to 
reduce the rate of CD4 loss and the impaired expression of the IL-7Rα irrespective of the 
state of cell differentiation raises concerns regarding the use of IL-7 therapy in HIV-1 
infection. 
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Introduction 
 
Interleukin-7 (IL-7) is considered a key cytokine in T-cell homeostasis acting both during 
thymopoiesis and in the periphery promoting naive T-cell proliferation and survival, as well 
as the maintenance of memory cells (1-4). Thus, much expectation has been placed on the 
therapeutic use of IL-7 to improve thymic output and broaden the T-cell repertoire in 
lymphopenic clinical settings, as well as an adjuvant to improve the breadth of vaccine 
responses (5-10).  IL-7 is constitutively produced by stromal cells of the bone marrow, 
thymus, mucosal lymphoid tissues, and lymph nodes (11-14). Circulating IL-7 levels increase 
in lymphopenic states, suggesting either a feed-back compensatory increased production or 
an increased availability due to the reduction in cell targets (1, 14-16). Increasing data point 
to a critical role of the expression of the α-chain of the IL-7 receptor (IL-7Rα) in the 
regulation of IL-7 biology (17, 18). IL-7 signaling results in a transient down-regulation of 
the IL-7Rα that is thought to allow adequate sharing of available IL-7 by a large number of 
T-cells (17). Moreover, IL-7Rα can also be down-regulated by other cytokines that share the 
common cytokine receptor chain γc, such as IL-2, and by TCR stimulation (19, 20). Of note, 
differentiated effector T-cells have been shown to be IL-7Rαlow
 
, a phenotype associated with 
decreased survival and proliferation in response to IL-7 (21, 22). HIV-1 infection is 
associated with high levels of circulating IL-7 (1, 14, 23-25), as well as with a decreased 
expression of IL-7Rα on T-cells (24-29).  
HIV-2, the second AIDS virus, is considered a “natural” model of attenuated HIV disease 
because it is associated with a much slower course of disease progression than HIV-1 with 
limited impact on the survival of the majority of infected adults (30, 31). More than 90% of 
HIV-2 infected individuals are thought to meet the standard criteria for “long-term non-
progressors” (30-32), but display a steady decline of CD4 counts (30, 32-34). Although the 
rate of CD4 depletion is markedly slower in HIV-2 than in HIV-1 infection, a direct 
correlation with the levels of immune activation was observed in both cases (34, 35). This is 
despite the low levels of viremia that characterize all the stages of HIV-2 disease (33, 34, 36-
38). The reduced viremia is considered the main reason why HIV-2 infection remains 
confined to West Africa (39-41). In Portugal, due to its connections with its past-colonies, 
there is a significant prevalence of HIV-2, currently accounting for 5% of the HIV infections 
(42). 
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We took advantage of this situation and compared untreated HIV-1 and HIV-2 infected 
patients living in Portugal in order to obtain insights into the role of IL-7 in the rate of CD4 
decline and the imbalances of T-cell subsets associated with HIV/AIDS pathogenesis as well 
as on the regulation of IL-7 in other lymphopenic states. 
 
We found that a delayed increase in IL-7 levels during the progressive depletion of 
circulating CD4 T-cells as well as a dissociation between the acquisition of markers of T-cell 
effector differentiation and the loss of IL-7Rα expression, are distinctly observed in HIV-2 
disease.  
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Patients and Methods 
 
Studied populations  
A cross sectional study involving 45 HIV-2 and 62 HIV-1 infected patients, currently living 
in Portugal and attending outpatient’s clinics in Lisbon, with no evidence of ongoing 
opportunistic infections or tumours, was performed. The clinical and epidemiological data of 
the 2 cohorts, as well as of the healthy controls, are summarized in Table I. Additionally, a 
longitudinal study was performed in 9 HIV-2 infected patients.  All subjects gave informed 
consent to blood sampling and processing and the study was approved by the Ethical Board 
of the Faculty of Medicine of Lisbon. 
 
 
 
Table I: Clinical and epidemiological features a 
a Data are mean ± SEM with limits in brackets, unless indicated otherwise. NA, not applicable. 
b Statistical differences between a given HIV infected cohort and the healthy controls. *, p<0.05; **, p<0.0001. Statistical 
differences between HIV-1and HIV-2 infected patients. #, p<0.05. 
c HIV-2 viremia was quantified and was <200 RNA copies/ml (cut-off) in 37 of the 42 patients studied.  
d 
 
HIV-1 viremia was quantified and was <50 RNA copies/ml (cut-off) in one of the 62 patients studied.  
 
Healthy controls HIV-2 infected patients HIV-1 infected patients b b 
    Number (male/female) 50 (18/32) 45 (13/32) 62 (36/26) 
Age (yrs)  41±2 (21-84) 48±2 (21-70) 37±1 (20-68) 
Ethnicity    
Caucasian 44 23 40 
Other 6 22 22 
HIV transmission category    
Heterosexual NA 35 37 
Homosexual/bisexual NA 2 13 
Intravenous drug user NA 1 8 
Blood transfusion NA  5 0 
Other/Unknown NA 2 4 
CD3 count (cells/µL) 1692±84 (767-3488) 1408±91 (427-2629)* 1353±78 (261-3430)* 
Percentage CD3 (%)  75±1 (58-86) 72±1 (48-87) 73±1 (44-94) 
CD4 count (cells/µL) 1058±56 (476-2387) 585±53 (28-1436)** 441±39 (2-1919)** # 
Percentage CD4 (%) 47±1 (33-65) 29±2 (2-48)** 24±1 (0.1-48)** # 
CD8 count (cells/µL) 572±39 (166-1251) 765±64 (180-2203)* 832±57 (127-2210)* 
Percentage CD8 (%) 25±0.9 (9-38) 40±2 (17-74)** 44±2 (13-86)** 
Viremia (RNA, copies/ml) NA 508±113 (200-4006) 157251±56017 (50-3072400)#  c 
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Phenotypic and intracellular characterization of lymphocyte subsets 
PBMC were isolated from fresh heparinized blood using Ficoll-Hypaque density separation 
gradient. PBMC were surface stained as previously described (34) with the following anti-
human mAbs (clone specified in brackets): CD8 (RPA-T8), CD27 (M-T271), CD45RA 
(HI100), CD62L (SK11), CD31 (WM59), and mouse IgG1, IgG2b isotype controls (all 
FITC-conjugated), CD8 (RPA-T8), CD45RO (UCHL-1), CCR7 (3D12), CD62L (Dreg 56), 
and mouse IgG1 and IgG2a isotype controls (all PE-conjugated), CD3 (SK7), CD4 (SK3), 
CD8 (SK1) (all PerCP-conjugated), CD8 (RPA-T8), CD4 (SK3), CD45RA (HI100), and 
mouse IgG1 and -IgG2b isotype controls (all Allophycocyanin-conjugated), all from BD 
Biosciences (San Jose, CA); and IL7-Rα (40131.111) PE-conjugated from R&D Systems 
(Minneapolis, MN). For the intracellular Bcl-2 staining, cells were fixed with 2% 
formaldehyde and permeabilized with PBS/1% BSA/0.5% saponin before staining with 
FITC-conjugated mAb (Bcl-2/100, BD Biosciences). Fifty thousand events were acquired 
using a FACSCalibur flow cytometer and analysed using Cellquest software (BD 
Biosciences). Briefly, a lymphocyte gate was manually set using forward and side-scatter, 
and thresholds were set according to isotype-matched controls. Absolute numbers of 
lymphocyte subsets were found by multiplying their representation by the absolute 
lymphocyte count obtained at the clinical laboratory.  
 
IL-7 Quantifications 
IL-7 levels were quantified in serum using the high sensitivity IL-7 Quantikine HS ELISA kit 
(R&D Systems), according to manufacturer’s instructions. Samples were assayed in 
duplicate. 
 
Plasma Viral Load Assessment 
HIV-1 viremia was quantified by RT-PCR (Ultrasensitive Test; detection threshold - 50 RNA 
copies/ml; Roche Molecular Systems, Branchburg, NJ). HIV-2 viral load was quantified 
using a RT-PCR based assay developed and performed by P.Gomes and M.H.Lourenço (42), 
which has a detection limit of 200 RNAcopies/ml. The cut-off value of the tests was 
considered for the purpose of the analysis in the cases where detection was below this level. 
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Quantification of Cellular proviral DNA load 
Genomic DNA was extracted from 106 PBMC cells using AbiPrism 6100 Nucleic Acid 
Extractor (Applied Biosystems, Foster City, CA) according to the manufacture’s instructions, 
and quantified using NanoDrop ND-100 spectrophotometer (NanoDrop Tecnologies, 
Wilmington, DE). Quantitative real-time PCR was performed in 50µl PCR mixture volume 
containing 25µl of Platinum Quantitative PCR SuperMix-UDG , 1µl ROX Reference Dye 
50X , 5 mM of MgCl2 (all from Invitrogen, Carlsbad, Ca), with 300 nM of each primer, 200 
nM of TaqMan probe and 150 ng of DNA using a AbiPrism 7000 SDS (Applied Biosystems). 
Thermal cycling conditions were as follows: 2 min at 50 oC, 2 min at 95 oC, followed by 40 
cycles for 15 sec at 95 oC and 1 min at 60 oC. HIV-1 and HIV-2 gag primers and FAM-MGB 
probes were designed in Primer Express 2.0 software (Applied Biosystems) and checked 
against the Los Alamos HIV database. The sequence of the primers and probes are as 
follows: Albumin Forward primer (AlbF): 5'- tgc atg aga aaa cgc cag  taa - 3'; Albumin 
Reverse primer (AlbR): 5'- atg gtc gcc tgt tca cca a- 3'; Albumin Probe: 5'- FAM- tca cca aat 
gct gca cag a - MGB - 3'; HIV-1 Forward primer (HIV-1-2F): 5'- ggg aga att aga tcg atg gga 
aa - 3'; HIV-1 Reverse primer (HIV-1-2R): 5'- ctg ctt gcc cat act ata tgt ttt aat tta - 3'; HIV-1 
Probe: 5'- FAM- ccc tgg cct taa ccg aat t - MGB - 3'; HIV-2 Forward primer (HIV-2-2F): 5'- 
cgc gag aaa ctc cgt ctt g - 3'; HIV-2 Reverse primer (HIV-2-2R): 5'- cac aca ata tgt ttt agc ctg 
tac ttt tt - ´3'; HIV-2 Probe: 5'- FAM - ccg ggc cgt aac ct - MGB - 3'. For each run, standard 
curves were generated from purified Albumin, HIV-1 gag and HIV-2 gag plasmids, ranging 
from 106 to 5 copies. Samples were run in duplicate and the input level of DNA was 
normalized to the albumin copy number. Data were expressed as number of HIV DNA copies 
per 106
 
 PBMC.  
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 4.00 (GraphPad Software, 
San Diego, CA). The data are presented as arithmetic mean±SEM and were compared using 
analyses of variance (ANOVA) and unpaired t test. Pearson’s correlation coefficient was 
used to assess the correlation between 2 variables. p<0.05 was considered to be significant. 
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Results  
 
Strong correlation between the increase in circulating IL-7 and the CD4 depletion in HIV-2 
infection  
 
Serum IL-7 levels were significantly increased both in HIV-1 and HIV-2 infections as 
compared to healthy controls, and there were no significant differences between the two 
infections (Figure 1A). On the other hand, we found a strong correlation between the 
increased levels of circulating IL-7 and the degree of CD4 depletion (p<0.0001, r= -0.5929) 
in HIV-2+ patients, that contrasts with the absence of a significant correlation in our HIV-1 
cohort (Figure 1B). This cohort, like the HIV-2 cohort, did not include a significant 
proportion of patients with extreme CD4 lymphopenia, which might explain the discrepancy 
between our data and the previous reports of a significant negative correlation between CD4 
counts and IL-7 levels in HIV-1 infection. In these cases, the significance was usually 
reached due to the very high IL-7 levels exhibited by patients with less than 100 CD4 cells/µl 
(1, 14, 23-25).  
In order to further clarify the relationship between IL-7 levels and disease progression, HIV-1 
and HIV-2 infected patients were divided into three groups according to CD4 T-cell counts: 
>500 (early), 200-500 (intermediate) and <200 CD4 T-cells/µl (advanced). Although both 
HIV-2 and HIV-1 patients at intermediate and advanced stages of disease exhibited 
significantly higher IL-7 levels than healthy controls, increased IL-7 levels in early disease 
stage was only observed in HIV-1 infected patients (Figure 1C). Thus, the absence of 
elevated IL-7 in early disease may contribute to the strong correlation documented between 
IL-7 and CD4 lymphopenia in HIV-2 infection.  
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     A          B 
 
 
 
 
 
 
 
 
 
 
    C 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Strong inverse correlation between circulating IL-7 levels and CD4 T-cell counts in 
HIV-2 infection.  
(A) Serum IL-7 levels in HIV-1 and HIV-2 infected and healthy subjects were assessed by ELISA. 
Each dot represents one individual and bars represent means. (B) Correlation between serum IL-7 
levels and CD4 T-cell counts in HIV-1 infected patients (open circle/black line), HIV-2 infected 
patients (grey circle/grey line) and healthy controls (black circle/dashed line). (C) Analysis of serum 
IL-7 levels in different sub-groups of HIV-1 and HIV-2 infected patients stratified according to CD4 
T-cell counts. Bars represent mean±SEM. The overall differences were highly significantly p<0.0001 
as assessed by ANOVA. Differences between two groups were compared by t tests. There were no 
statistically significant differences between HIV-1 and HIV-2 subgroups when comparing similar 
levels of CD4 depletion.  Statistical significance between the different HIV infected groups as 
compared to healthy subjects: * p<0.05; ** p<0.01 and *** p<0.001.  
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The strong correlation between IL-7 and CD4 lymphopenia observed in HIV-2 infection is 
further supported by longitudinal studies of HIV-2 infected patients 
 
A longitudinal analysis of circulating IL-7 levels and CD4 T-cell counts was performed in 
nine HIV-2 infected patients.  As shown in Figure 2, low CD4 T-cell counts were associated 
with increased IL-7 levels in all patients. The period of follow-up ranged from 2 to 9 years. 
These untreated HIV-2 infected patients exhibited a reduced rate of CD4 decline as expected 
(32, 33, 36, 42). The graphs illustrate the consistency of the IL-7 measurements during 
follow-up and document changes in serum IL-7 levels inversely related to the alterations 
found in CD4 T-cell counts.  
 
 
 
Figure 2 – Longitudinal analysis of circulating IL-7 levels and CD4 T-cell counts in HIV-2 
infected patients.  
Each graph illustrates the serum IL-7 levels (black circles) and the CD4 T-cell count (open circles) in 
each HIV-2 infected individual infected during disease follow-up.  
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No correlation of serum IL-7 levels with age 
 
It has been suggested that serum IL-7 levels decreases with age (43, 44). Since HIV-2 
infected patients tend to be older than HIV-1 infected subjects we looked for a possible 
impact of age on the circulating IL-7 levels and found no correlation between age and serum 
IL-7 in our three cohorts as illustrated in Figure 3A. Moreover, there were no statistically 
significant differences in IL-7 levels according to gender in the infected cohorts (p=0.1194 
derived from the analysis of variance). 
 
No significant correlation of serum IL-7 levels with viremia and proviral DNA 
 
IL-7 is a powerful inducer of HIV-1 replication in vitro (45). However, there is conflicting 
data regarding the correlation between circulating IL-7 and HIV-1 viremia (1, 14). We found 
no correlation between serum IL-7 and HIV-1 viremia (r=0.0324, p=0.8094). Despite the lack 
of data on the ability of IL-7 to induce HIV-2 replication, it is unlikely that it will have a 
different effect to that reported for HIV-1 and SIV strains (45-47). Since the large majority of 
the HIV-2 infected patients had undetectable levels of viremia (below 200 RNA copies/ml), it 
was impossible to correlate this parameter with IL-7 levels.  
In spite of the distinct viremia, HIV-1 and HIV-2 infected patients have been shown to have 
comparable levels of cell-associated viral load as assessed by proviral DNA (36, 48, 49). 
Accordingly, we found no significant difference between the levels of PBMC proviral DNA 
in the HIV-1 and HIV-2 cohorts. No correlation was found between circulating IL-7 and 
HIV-1 proviral DNA as well as with HIV-2 proviral DNA, as shown in Figure 3B.  
 
Analysis of CD4 T-cell subsets / IL-7Rα expression in relation to circulating IL-7 
 
We then investigated whether the apparent close association of increased IL-7 levels with 
CD4 depletion in HIV-2 infection had an impact on naive/memory imbalances and on IL-
7Rα expression as assessed by flow cytometry on freshly isolated PBMC.  
As illustrated in Figure 4A, a significant negative correlation was found between circulating 
IL-7 levels and naive CD4 T-cell counts in the HIV-2 cohort that was not observed in the 
HIV-1 cohort.  
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A       B 
 
 
 
Figure 3 – No significant correlation between circulating IL-7 levels with age or virological 
parameters.  
Correlation between serum IL-7 levels with: (A) age in healthy subjects as well as HIV-2 and HIV-1 
infected patients and (B) PBMC associated proviral load quantified by real-time PCR in both HIV-2 
and HIV-1 infected cohorts. Each dot represents one individual: healthy (black circle), HIV-1 infected 
(open circle) or HIV-2 infected (grey circle). The HIV-2 and HIV-1 cohorts evaluated do not differ 
significantly in terms of either CD4 counts or IL-7 levels. 
 
 
The CD31 molecule has been proposed to be a marker for recent thymic emigrants as the 
CD31+ subset of human naive T-cells is enriched in T-cell receptor excision circles  (TREC) 
(50). When we looked for a correlation between IL-7 and the proportion of CD31+ cells 
within the naive CD4 subset, the linear regression showed a similar marked positive slope 
both in HIV-2 and healthy cohorts that contrasts with the negative slope found in the HIV-1 
cohort (Figure 4B). Moreover, this correlation reaches significance when the number of 
subjects is increased by the conjoint analysis of the HIV-2 and healthy cohorts (r= 0.3876; p= 
0.0312). Although there were no significant differences between the frequency of CD31+ 
cells within the naive CD4 subset in the three cohorts (HIV-2: 48.41±6.43; HIV-1: 
43.87±3.57; and healthy: 42.50±3.11), the expected decline of this frequency with age was 
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not observed in HIV-2 infected patients (Figure 4C). Further studies are required to elucidate 
the relative contribution of the thymus and the periphery in the maintenance of this 
population, including TREC quantification. Despite this, our data suggest that the better 
preservation of this subset in HIV-2 than in HIV-1 infected patients is closely related to IL-7 
levels. 
 
Figures 4D and 4E illustrate the IL-7Rα expression levels within the naive and memory CD4 
subsets, respectively. The HIV-2 patients included in this analysis were older than the HIV-1 
patients (49±3 and 37±3 yr, respectively, p= 0.0058), but had similar CD4 counts and IL-7 
levels. As expected, in all three cohorts there was a significant decrease in the levels of IL-
7Rα (p<0.006), with cell differentiation defined by the loss of CD45RA. The HIV-1 infected 
patients exhibited a major reduction in the IL-7Rα expression as compared to healthy 
controls both in the naive and memory subsets, in agreement with the low levels of IL-7Rα 
expression in HIV-1 infected patients reported by others (24, 26, 27). However, in HIV-2 
infected patients, there was only a significant decrease in IL-7Rα expression in the memory 
subset, suggesting maintenance of the IL-7Rα in the naive CD4 pool. The levels of CD4 T-
cell activation as assessed by HLA-DR up-regulation were similar in the two infections (data 
not shown), suggesting that the discrepancies of IL-7Rα expression cannot be attributed to 
different states of T-cell activation. 
 
The ability of IL-7 to promote T-cell survival has been shown to be related to the up-
regulation of the antiapoptotic molecule Bcl-2 (3). We measured intracellular Bcl-2 by flow 
cytometry on freshly isolated PBMC, and, despite an apparent trend in HIV-2 infected 
patients for higher MFI (median intensity of fluorescence) within the CD4 subset, no 
significant differences were found in the three cohorts (Figure 4F).  
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A     B    C 
 
 
D     E    F 
 
 
 
Figure 4 – Analysis of CD4 T-cell subsets and IL-7Rα expression  
PBMC from HIV-1 and HIV-2 infected patients, as well as healthy controls were phenotypically 
characterized using 4 color flow cytometry. (A). Correlation between serum IL-7 levels and 
circulating naive CD4 T-cell counts, as defined by the simultaneous expression of CD45RA and 
CD62L. The naive subset was further characterized in terms of the expression of CD31 and the 
correlation between the proportion of CD31+ cells within the CD4 naive subset and serum IL-7 levels 
(B) and age (C) was analyzed. Frequency of IL-7Rα+ 
 
cells within the naive (D) and the memory (E) 
CD4 subsets; the overall differences were significant as assessed by ANOVA (p=0.001 and p=0.022, 
respectively), and the significant p values of the differences between two groups evaluated by t test 
are shown.  (F) Median fluorescence intensity of intracellular Bcl-2 within CD4 T-cells. Each dot 
represents one individual: HIV-1 infected patients (open circle), HIV-2 infected patients (grey circle) 
and healthy controls (black circle). Bars represent means. The studied HIV-2 and HIV-1 cohorts had 
comparable CD4 counts and IL-7 levels. 
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Analysis of CD8 T-cell subsets / IL-7Rα expression in relation to circulating IL-7 
 
CD8+ T cell differentiation was assessed by the expression of CD27, CCR7 and CD45RA in 
cohorts of HIV-2 and HIV-1 infected patients with comparable degrees of CD4 counts and 
IL-7 levels but differing viremia. We found similar levels of naive and central memory CD8 
T-cell pool depletion in both infections (Figure 5A and 5B, respectively). However, HIV-1 
infected patients exhibited an expansion of CD8+ T-cells with an intermediate-differentiated 
phenotype CD45RA-CCR7-CD27+, which was not found in the HIV-2 cohort (Figure 5C). In 
fact, the major CD8 expansion observed in HIV-2 infected patients was essentially due to 
terminally-differentiated effector cells CCR7-CD27-CD45RA+
All the three cohorts exhibited a progressive loss of expression of IL-7Rα in the CD8 
subpopulations as they acquired a more differentiated phenotype. However, HIV-2 and HIV-
1 infected patients exhibited significantly lower expression levels of IL-7Rα in all the CD8 
subsets as compared to healthy controls (Figure 5E). When we compared both infected 
cohorts, the HIV-2 infected patients preserved significantly higher levels of IL-7Rα 
expression than the HIV-1+ patients in all the CD8 effector-memory subpopulations (Figure 
5E).  A similar level of CD8 activation assessed by CD38 and/or HLA-DR was observed in 
the two infected cohorts (data not shown), and, therefore, it is unlikely that the discrepant 
levels of IL-7Rα expression in the two infections were due to differences in the cell-
activation state.  
 (Figure 5D).  These results are 
in agreement with our previous data from other HIV-2 and HIV-1 cohorts where CD8 
differentiation was assessed by CD62L, CD28 and CD27 expression as well as IL-2 and/or 
IFNγ production (34, 38). No significant correlations were found between serum IL-7 levels 
and the frequency of the different CD8 subsets in either infection. 
In summary, the expanded CD8 T-cell pool, observed in both HIV cohorts, showed skewing 
towards a terminally differentiated effector phenotype paralleled by a better preserved 
expression of IL-7Rα in the HIV-2+ as compared to the HIV-1+ individuals. 
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A     B    C   
 
 
D      E 
 
Figure 5 – Imbalances of CD8 T-cell subsets and IL-7Rα expression. 
CD8 T-cell subsets were defined by the simultaneous analysis of CD45RA and CCR7 or CD27 by 
flow cytometry using freshly isolated PBMC. Analysis of the frequency of naive CCR7+CD45RA+ 
(A), central-memory CCR7+CD45RA- (B), intermediate CCR7-CD45RA- (C), and terminally-
differentiated CCR7-CD45RA+ (D) within the CD8 T-cells. Each dot represents one individual: HIV-1 
infected (open circle), HIV-2 infected (grey circle) and healthy (black circle). Bars represent means. 
(E) IL-7Rα expression was assessed within successive subsets of CD8 T-cell differentiation, namely, 
CD45RA+CD27+, CD45RA-CD27+, CD45RA-CD27- and CD45RA+CD27- in 18 HIV-1 infected 
patients, 12 HIV-2 infected patients, and 22 healthy controls. The studied HIV-2 and HIV-1 cohorts 
had comparable CD4 counts and IL-7 levels. The overall differences between the groups were 
statistically significant p<0.005 to p<0.0001 assessed by ANOVA. Bars represent mean±SEM. 
Statistical significance between the different HIV infected groups as compared to healthy subjects: * 
p<0.05; ** p<0.01 and *** p<0.001 and between HIV-1 and HIV-2 infected patients: # p<0.05 and ## 
p<0.01 as assessed by t test. 
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Discussion 
 
This is the first study evaluating both the levels of circulating IL-7 and the expression of the 
IL-7Rα in patients infected with the second AIDS-associated virus, the HIV-2. HIV-2 disease 
has several unique features that make it especially attractive to address the role of IL-7 in 
lymphopenic clinical settings. Firstly, it is characterized by a progressive decrease in CD4 
counts associated with pan-immuneactivation, though at a much slower rate than that 
observed in HIV-1 infection (30, 32-34). Secondly, in contrast with HIV-1, HIV-2 infection 
is associated with reduced viremia at all disease stages (33, 34, 36-38). Thirdly, it has a 
relatively favorable clinical outcome with limited impact on the mortality of the majority of 
the infected adults (30-32), suggesting that HIV-2 infected patients somehow retain the  
capacity to replace and sustain numbers of immunologically competent CD4 T-cells.  
 
Here, we describe an increase in circulating IL-7 levels in strong correlation with the degree 
of CD4+
 
 T-cell depletion. This was documented in a cross-sectional study involving HIV-2 
patients with different levels of CD4 counts without known ongoing opportunistic infections, 
as well as in a longitudinal study. This cohort was compared with an HIV-1 infected cohort, 
similarly underrepresented by profoundly lymphopenic patients, which may explain the 
absence of this correlation in contrast to the majority of the HIV-1 studies reported in the 
literature (1, 14, 23-25).  
The mechanisms driving increased circulating IL-7 levels remain unclear (1, 16). Two non-
mutually exclusive explanations have been proposed. 
 
Elevated IL-7 levels may result from increased production in response to the CD4 
lymphopenia (1, 14, 15). This would require a more marked CD4 loss in HIV-1 than in HIV-
2 infected patients despite the same levels of peripheral blood CD4 counts, in order to explain 
the disease specific differences in the kinetics of IL-7 increase in early infection. We found 
similar levels of circulating IL-7 in early HIV-2 disease and healthy subjects, in contrast to 
the significant increase found in early HIV-1 infection. However, there is cumulative 
evidence that during early HIV-1 disease the peripheral blood compartment overestimates the 
degree of CD4 depletion of the body due to the traffic alterations that promote lymphocyte 
retention in the lymphoid tissue as illustrated through the study of tonsils and lymph nodes 
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(51, 52). Yet, recent data show a marked depletion of CD4+
 
 T-cell subsets in the gut, 
occurring during acute HIV-1 infection and persisting throughout disease (53-55). There are 
no data on lymph node or mucosal pathology during HIV-2 infection, but it is reasonable to 
speculate that the establishment of HIV-2 infection may not be associated with a high viremia 
peak and major depletion of the memory compartment, given the absence of clinical reports 
of HIV-2 acute infection. The possible contribution of gut-associated CD4 depletion in 
triggering the early increase of IL-7 production in HIV-1 infection deserves further 
exploration. 
Alternatively, the circulating IL-7 levels may increase as a result of its diminished adsorption 
by a reduced number of cells expressing the IL-7Rα (16). Our findings support this 
possibility given the reduced levels of IL-7Rα expression in HIV-1 as compared to HIV-2 
infected patients with the same degree of CD4 depletion. Although, IL-7 consumption has 
been shown to transiently induce IL-7 down-regulation, the high IL-7 levels observed in 
HIV-1 infection argue against this explanation. The different IL-7Rα expression in the two 
infections is particularly relevant in view of the similar state of immune-activation as 
assessed by the expression of HLA-DR and CD38 within both CD4 and CD8 T-cell subsets, 
in agreement with our previous studies in other cohorts using a larger panel of activation 
markers (34, 56). Moreover, several factors would favor a lower level of expression of the IL-
7Rα in HIV-2 infection, namely: HIV-2 infected patients were shown to be older, and, ageing 
is associated with impaired IL-7Rα expression (22); the longer length of the infection in the 
case of HIV-2; and the terminally differentiated profile exhibited by the CD8 T cells of these 
patients.  
 
IL-7 administration to SIV infected non-human primates has been shown to expand naive and 
memory T cell subsets (6, 9, 10). Although the frequency of naive and central memory T-
cells were not higher in HIV-2 as compared to HIV-1 infected patients with the same degree 
of CD4 depletion, it is possible that a well adjusted and balanced increase in circulating IL-7 
levels may contribute to the slower rate of loss of these populations in HIV-2 infection. 
Moreover, almost all subsets of CD4 and CD8 T cell, irrespectively of their differentiation 
state, were shown to have higher levels of IL-7Rα expression in HIV-2 than in HIV-1 
infected patients, possibly indicative of a higher proliferative capacity or survival in response 
to IL-7. The preserved expression of the IL-7Rα, in particular within the CD4 naive T-cells, 
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could also lead to an increased consumption of IL-7 in HIV-2 as compared to HIV-1 
infection, and partly explain the delayed increase in circulating IL-7 levels. 
 
On the other hand, IL-7 is a strong inducer of HIV-1 replication (45, 57, 58), leading to its 
proposed use as a therapy to purge the viral reservoirs in HIV-1 infected patients virally 
suppressed by ART (45). Although there are no data on the ability of IL-7 to promote HIV-2 
replication, it would be expected to be comparable given the similarity of the two viral 
promoter regions (LTRs) (59). No differences were found between the levels of HIV-2 and 
HIV-1 proviral DNA in PBMCs, in agreement with other studies (36, 48, 56). The low to 
undetectable HIV-2 viremia in this context further emphasizes the efficiency of the ill-
defined mechanisms involved in the control of viral replication in HIV-2 infected patients in 
the absence of antiretroviral therapy.  
 
In summary, this comparison of two persistent infections associated with progressive CD4 
depletion and immune-activation demonstrates the better prognosis is not necessarily 
associated with higher levels of IL-7. Moreover, the delayed increase in IL-7 levels, coupled 
with sustained expression of IL-7Rα suggests a maximization of available resources. The 
observation that increased IL-7 levels early in HIV-1 infection seem unable to reduce the rate 
of CD4 loss, and the impaired expression of the IL-7Rα irrespective of the state of cell 
differentiation raises concerns regarding the use of IL-7 therapy in HIV-1 infection. 
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EFFICIENT THYMOPOIESIS CONTRIBUTES TO THE MAINTENANCE OF 
PERIPHERAL CD4 T CELLS DURING CHRONIC HUMAN IMMUNODEFICIENCY 
VIRUS TYPE 2 INFECTION. 
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Abstract 
 
Human immunodeficiency virus type 2 (HIV-2) infection leads to a lifelong asymptomatic 
period in the majority of patients. Even in patients with progressive disease, a slow CD4 
count decline characterizes the chronic phase of HIV-2 infection, suggesting that peripheral 
T-cell homeostasis is controlled better following HIV-2 infection than following HIV-1 
infection. Herein we showed that, in contrast to HIV-1-infected patients, HIV-2-infected 
patients demonstrate enhanced thymic function compared to age-matched healthy individuals. 
The correlation between higher thymic production and lower CD4 T-cell loss in these 
patients suggests that efficient thymopoiesis is implicated in the long-lasting maintenance of 
CD4 T-cell counts in HIV-2 disease. 
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Human immunodeficiency virus type 2 (HIV-2) infection is associated with a more benign 
course of disease than HIV-1 infection is. The majority of HIV-2-infected individuals remain 
asymptomatic for years following infection and their disease behaves like that of HIV-1-
infected long-term nonprogressors, while the patients who progress to disease exhibit a much 
slower rate of CD4 decline than the rate for HIV-1-infected patients (9, 12, 21). The latter 
group of HIV-2-infected patients is reminiscent of HIV-1 slow progressors, characterized by 
a slow CD4 T-cell decline despite detectable viremia (3, 13). Furthermore, studies in 
geographic areas where high HIV-2 prevalence is observed demonstrated that the life 
expectancy for individuals with HIV-2 infection is often close to that of uninfected 
individuals living in the same villages (12).  
 
The factors determining the delayed disease progression in HIV-2 infection remain largely 
unknown (14). Although plasma viral load is much lower in HIV-2 infection than in HIV-1 
infection (2), the proviral loads of HIV-2-infected patients are similar to those of HIV-1-
infected patients at the same disease stage (10, 11), suggesting that the two viruses do not 
differ significantly in their ability to establish infection and replicate in human cells (1, 17). 
On the other hand, similar degrees of T-cell hyperactivation, as well as increased T-cell 
cycling, were observed for both HIV-1- and HIV-2-infected patients with similar degrees of 
CD4 depletion (18). This suggests an intimate link between generalized immune activation 
and associated cell death and CD4 depletion in both infections despite distinct viremias and 
clinical outcomes. 
 
HIV-1 infection is associated with an impairment of intrathymic precursor T-cell 
proliferation resulting in a huge reduction of de novo T-cell production thought to participate 
in the progressive decline of peripheral CD4 T-cell counts, in particular in the recent thymic 
emigrants (RTEs) and naive T-cell compartments (4). An imbalance between production and 
destruction of peripheral CD4 T-cells would lead to their progressive decline over time and 
eventually to AIDS (5, 6). Moreover, in slow progressor HIV-1-infected patients, we recently 
demonstrated that the maintenance of circulating CD4 T-cells is strongly associated with 
efficient thymopoiesis (3). 
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We thus hypothesized that the maintenance of de novo T-cell production may counteract the 
peripheral CD4 loss that is known to occur in HIV-2 infection and represents a major 
mechanism underlying the slow progression of HIV-2 disease. Here we analyzed the role of 
thymopoiesis in the long-term maintenance of peripheral CD4+
 
 T-cell numbers in a cohort of 
untreated chronically HIV-2- and HIV-1-infected subjects currently living in Portugal and 
attending outpatient clinics in Lisbon, Portugal, compared to age-matched healthy 
individuals. A summary of the clinical features of the patients studied and healthy controls is 
shown in table 1. 
 
 
Table 1. Characteristics of the HIV-1- and HIV-2-infected patients and healthy controls studied 
Characteristic 
Value for group a 
Controls HIV-1-infected patients HIV-2-infected patients 
35 to 45 yr >45 yr 35 to 45 yr >45 yr 35 to 45 yr >45 yr 
No. of subjects 11 12 6 9 7 13 
Ethnicity 9 C; 2 A b 11 C; 1 A 5 C; 1 A 6 C; 3 A 4 C; 3 A 7 C; 6 A 
Age (yr) 
39 c 
(36-45) 
54 
(46-65) 
41 
(35-43) 
54 
(46-65) 
38 
35-45) 
49 
(46-68) 
Time (mo) after first 
Seropositivity 
NA c,d 
NA ND ND 
19 
(7-133) 
18 
(2-172) 
Viral load 
(log copies/ml)
NA c 
NA 
4.06 
(2.63-4.98) 
4.55 
(3.28-5.41) 
<200 
<200 
e (<200-
4006) 
e 
Absolute CD4 count 
(cells/ml) 
920 
c (535-1867) 
882 
(347-1758) 
291** 
(92-704) 
240** 
(88-986) 
927 
(333-1184) 
593* 
(220-830) 
Absolute CD8 count 
(cells/ml) 
336 
c (105-1236) 
265 
(99-770) 
654* 
(269-2007) 
781** 
(518-2210) 
845* 
(611-1778) 
670** 
(202-2180) 
 
a The subjects are grouped by disease status (controls and HIV-1- and HIV-2-infected patients) and age. NA, not applicable; 
ND, not determined. Statistical differences between the values for HIV-infected patients and age-matched controls (Mann-
Whitney test) are indicated as follows: *, P <0.05; **, P <0.01. 
b The number of Caucasians (C) and Africans (A) are shown (all the African subjects had been residing in Europe for several 
years at the sampling time). 
c The median value is shown, and the range is shown in parentheses. 
d All the HIV-2-infected individuals were identified as seropositive at their first visit. (The HIV-1 patients were sampled for 
another cross-sectional study.) 
e
  
 HIV-2 viremia was quantified by a reverse transcriptase PCR-based test; all but one of the HIV-2 infected patients had a 
viral load below 200 RNA copies/ml (cutoff value). 
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Thymic activity was estimated by measurement of the intrathymic proliferation history of 
circulating RTEs by quantification of the signal joint/beta T-cell receptor excision circle (sj/ 
βTREC) ratio as described previously (3, 4, 20). This marker, which is independent of 
peripheral T-cell proliferation and death rate, directly reflects the number of proliferation 
cycles undergone by precursor T cells during their intrathymic differentiation and thus thymic 
output (4).  
 
Surprisingly, while in both HIV-1 and HIV-2 patients, the younger individuals (35 to 45 
years old) demonstrate a low thymic function (median sj/ βTREC ratios of 11.3 and 6.5 for 
HIV-1 and HIV-2 patients, respectively, compared to a ratio of 24.1 in the healthy control 
group [P = 0.026 and P = 0.02, respectively]; Fig. 1A), a significantly higher sj/βTREC ratio 
characterizes HIV-2-infected subjects that were > 45 years old compared to healthy controls 
(median sj/βTREC ratio of 17.0 in HIV-2-infected patients compared to 4.9 in control 
individuals [P = 0.0047]; Fig. 1A). This contrasts with the expected low intrathymic 
proliferation observed in age-matched HIV-1-infected patients (sj/βTREC ratio of 6.9). In 
fact, analysis of the sj/βTREC ratio as a function of age shows that the expected age 
dependence of thymic output is not observed in the HIV-2-infected patients (Fig. 1B). While 
most patients with chronic HIV-1 infection demonstrate a rapid and persistent defect in 
thymic output (3, 4), the impairment of thymopoiesis observed in the younger groups of HIV-
2-infected patients is not further exacerbated by aging. In contrast, it seems that this function 
is maintained in this group of patients, so that in aged individuals, the sj/ βTREC ratio 
becomes greater than in healthy individuals, most likely leading to long-term sustained 
thymic output. 
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A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – HIV-2-infected patients demonstrate high thymic function.  
(A) The sj/βTREC ratio, a measure of thymic activity, was calculated for healthy individuals (controls 
[Ctrls]) and HIV-1- and HIV-2-infected patients. The three groups were subdivided into groups by 
age (35 to 45 years old and > 45 years old). Gray symbols represent healthy control individuals of 
African origin. Statistical differences (P values) between the different groups are shown above the 
values (Mann- Whitney test). NS, not significant. (B) Correlation between the sj/βTREC ratio and age 
in healthy controls (white and gray symbols, representing Caucasian and African individuals, 
respectively, and HIV-2-infected patients (black symbols). Spearman’s correlation and associated 
probability are shown for the control group. 
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Nevertheless, one must consider that the assessment of sjTREC frequency may be influenced 
by variable degrees of immune activation/proliferation in the groups studied. We thus also 
determined the sjTREC concentration (sjTREC/ml of blood) which, although influenced by 
thymic output and RTE survival, does not depend upon the general state of immune 
activation/proliferation (7, 8). 
 
Interestingly, the analysis of the sjTREC concentration also showed that the patients that 
were >45 years old behave like age-matched controls do, with a significant reduction 
characterizing 35- to 45-year-old individuals (median sjTREC/ml of 670 and 1,821 in HIV-2-
infected patients and controls, respectively; P = 0.02) (Fig. 2B). The parallelism between 
sjTREC frequency and concentration (Fig. 2A and B) suggests that the proliferation of 
TREC-positive cells is not of major importance in the regulation of naive T-cell counts 
during HIV-2 infection. However, HIV-2- and HIV-1-infected patients with equivalent 
degrees of CD4 depletion demonstrate similar enhancement of immune activation levels (18, 
19). It is thus most probable, as demonstrated by Sieg et al. in HIV-1 infection that T cells 
expressing activation/proliferation markers (CD69, HLA-DR, Ki-67. . .) in HIV-2 infection 
are also determined to die rapidly in vivo (15, 16). This is further emphasized by analyzing 
the relationships between the sj/βTREC ratio (thymic production) and the sjTREC 
concentration (approximate RTE counts). As expected, both parameters correlated nicely in 
the control group and the HIV-1-infected patients (r = 0.574 and P = 0.006 and r = 0.653 and 
P = 0.014, respectively [Fig. 2C, left graph]). In contrast, in HIV-2-infected patients, thymic 
production was not associated with RTE concentration (Fig. 2C, right graph), demonstrating 
that the sustained thymic function in older HIV-2-infected patients does not lead to the 
expected enlargement of the TREC-rich T-cell population, likely being concomitantly 
expanded by increased cell death and/or accelerated maturation. This is further emphasized 
by the absence of correlation between circulating interleukin 7 levels and sjTREC 
quantification in HIV-2-infected patients (1). 
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A      B 
 
 
C 
 
 
 
Figure 2 – Consequences of the increased thymic function on peripheral RTE population.  
(A) Relationships between the sjTREC frequency and age in HIV-2-infected patients and healthy 
control individuals. (B) Relationships between sjTREC concentration and age in HIV-2-infected 
patients and healthy control individuals. In both panels A and B, the white symbols and dashed lines 
represent healthy controls (gray dots represent healthy controls of African origin), and the black 
symbols and solid lines represent the HIV-2-infected patients. The P values from the statistical 
analysis (Mann-Whitney test) for each age group are shown above the values. NS, not significant. (C) 
Relationships between the sjTREC concentration and thymic function in healthy controls (white and 
gray symbols, representing Caucasian and African individuals, respectively), HIV-1-infected patients 
(left graph, black symbols), and HIV-2-infected patients (right graph). When significant, P values 
from the statistical analysis are shown (Spearman’s correlation and associated probability). 
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In order to estimate the impact of the observed enhanced thymopoiesis on the relative 
resistance to disease in the HIV-2-infected patients, we calculated the rate of CD4 count 
decline in this group of patients over a median period of 2.5 years preceding the analysis of 
thymic function. In HIV-2-infected patients, the sj/βTREC ratio tends to correlate with the 
variations in CD4 T-cell counts over time (r = 0.432 and P = 0.09; Fig. 3A). Such a 
correlation does not exist in the HIV-1-infected patients (r = 0.06 and not statistically 
significant). Interestingly, when classifying the patients according to their sj/βTREC ratio, a 
significant difference was observed in their capacity to maintain CD4 T-cell counts over the 
follow-up period. While patients demonstrating efficient thymopoiesis (i.e., sj/βTREC ratio 
of >10) preserve their CD4 T-cell counts over the follow-up period (median CD4 change of 
+25 cells/ year [range, -43 to +202]; Fig. 3B), patients with low sj/βTREC ratio (<10) show a 
slow but definite decline in circulating CD4 T-cell numbers (median loss of -40 cells/year 
[range, -217 to +19; P = 0.023]). In contrast, in the HIV-1- infected group, the extent of 
intrathymic precursor T-cell proliferation does not correlate with CD4 T-cell decline (median 
CD4 changes of -122 and -73 cells/year in patients with sj/βTREC ratios of <10 and >10, 
respectively; not statistically significant; data not shown).  
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 B 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Increased thymic output translates into maintenance of CD4 counts.  
(A) Relationships between the sj/βTREC ratio and CD4 changes over time in HIV-2-infected patients. 
The correlation coefficient (Spearman’s test) and associated probability are shown. (B) CD4 changes 
in HIV-2-infected patients with sj/βTREC ratios of <10 and ≥10. CD4 change values were calculated 
using the slope of CD4 counts measured over a period of >2.5 years before sampling. Statistical 
differences between the two groups (P values) are shown above the ratios (Mann-Whitney test). 
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Taken together, these data demonstrate that patients with chronic HIV-2 infections maintain 
thymic production for prolonged periods of time, even after they reach 45 years of age, when 
significant thymic involution is observed in healthy individuals. This effect, reminiscent of 
what was observed in HIV-1-infected slow progressors, suggests that increased CD4 T-cell 
death can, at least partly, be compensated for by an overproduction of new T cells in HIV-2-
induced pathology. The fact that younger HIV-2-infected patients demonstrate a reduced 
thymic function suggests either that HIV-2 infection can lead to various levels of 
pathogenesis or that sustained thymic function in aging patients is a mechanism that develops 
slowly to compensate for increased cell death. Patients who cannot maintain thymic function 
would exhibit progressively lower CD4 T-cell counts, eventually leading to AIDS, while 
others whose thymus remains functional maintain CD4 counts and remain asymptomatic for 
several decades. However, it is possible that efficient thymopoiesis is both a cause and 
consequence of limited pathogenicity in HIV-2. It is quite possible that low viral loads in 
HIV-2-infected patients, by inducing limited homeostatic perturbations, leads to maintained 
thymic potential and that when lymphopenia occurs, this capacity of the thymus to produce 
new T cells allows the maintenance of CD4 counts and naive T-cell diversity sufficiently 
high to limit progression of the disease.  
 
Interestingly, Poulsen et al. observed that in some West African villages, older people (55 to 
80 years of age) with HIV-2 infection have the same mortality risk as uninfected individuals 
do (12). The capacity of these patients to maintain de novo T-cell production through 
efficient thymopoiesis despite aging may participate to their longevity in the presence of 
HIV-2 infection.  
 
These new data on the role of the thymus in this natural model of attenuated HIV infection 
bring new arguments to the contribution of ongoing thymopoiesis for HIV pathogenesis and 
the rate of progression to AIDS and strengthen the importance of the thymus as a target for 
immune- based therapies. 
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HIV-1 infection is characterized by a progressive depletion of CD4 T cells that cannot be 
solely attributed to direct viral killing (1). The persistent and generalized immune activation 
contributes to a greater susceptibility of lymphocytes to apoptosis and/or anergy, and is 
thought to increase the outflow of naive T cells into the memory-effector compartment (1, 2). 
On the other hand, de novo T cell production in the thymus is impaired by HIV-1 infection 
(2).  The maintenance of the naive T cell pool is known to be due to homeostatic mechanisms 
of proliferation of peripheral T cells combined with an age-dependent contribution of thymic 
output. HIV-1 can directly and indirectly influence the production of various cytokines that 
regulate T cell homeostasis (3). Also, HIV-1 infects thymocytes and hematopoietic precursor 
cells and promotes the disruption of the thymic microenvironments necessary for the 
differentiation of T cells (4).  
 
HIV-2 infection is associated with a much slower progressive CD4 T cell decline than HIV-1 
infection. However both infections show similar levels of hyperimmune activation in parallel 
with CD4 depletion, throughout the natural history of the disease, despite the reduced viremia 
that characterizes HIV-2 infection (5). Thus, it is reasonable to expect that HIV-2 infected 
individuals have a better preserved ability of T cell replenishment. HIV-2 was used in this 
work, as a model of attenuated HIV disease, to provide insights into the alterations of the 
mechanisms necessary for the maintenance of the T cell pool during HIV pathogenesis. 
 
The role of the IL-7 network in lymphopenic clinical settings was addressed through the 
evaluation of both the levels of circulating IL-7 and the expression of the IL-7Rα in CD4 and 
CD8 T cells in a cross-sectional study involving HIV-2 and HIV-1 cohorts of patients paired 
for disease stage, as defined by CD4 counts. Also, thymic activity was estimated by the 
quantification of the signal joint/beta T cell receptor excision circle (sj/β TREC) ratio as 
described previously to indirectly assess intrathymic proliferation history (6-8). These data 
were correlated with the maintenance of peripheral CD4 T cell numbers in a cohort of 
untreated chronically HIV-2- and HIV-1-infected subjects.  
 
 
 
 
 130 
 
Part I – Conclusions and Future Perspectives 
 
In summary, the data presented here show that:  
 
i) there is a correlation between circulating IL-7 levels and the degree of CD4 T cell depletion 
in HIV-2 infection, which is much stronger than the one found in the HIV-1 cohort. At the 
advanced stages of infection, similar levels of circulating IL-7 levels were found in both 
HIV-2 and HIV-1 cohorts, which were significantly higher than in the healthy cohort. 
However, in contrast to HIV-1 infection, the levels of circulating IL-7 were not significantly 
increased in the early stages of HIV-2 infection (9).  
 
ii) the expression of the IL-7Rα was better preserved in all subsets of CD8 T cells and in 
memory CD4 T cells in HIV-2 in comparison with HIV-1 cohort, although there was a 
significant reduction in both cohorts as compared to the healthy controls. Moreover, a clear 
preservation of IL-7Rα expression in the naive CD4 T cells was shown in the HIV-2 cohort, 
with levels comparable to those found in healthy controls that did not occur in HIV-1 infected 
patients. (9).   
 
iii) HIV-2 infected patients presented with elevated sj/β TREC ratios, which were compatible 
with a maintained thymic production for prolonged periods of time. Of note, in the healthy 
controls after 45 years of age there was a reduction in the sj/β TREC ratios in agreement with 
the expected thymic involution. However, in the HIV-2 infected cohort the sj/β TREC ratios 
were maintained independent of age (10). 
 
Taken together, these data suggests that in HIV-2 infection, both thymopoiesis and the 
peripheral T cell homeostasis may be better preserved. 
 
IL-7 in HIV/AIDS Pathogenesis 
 
IL-7 is an essential cytokine for T cell homeostasis. In lymphopenic states, circulating IL-7 
levels increase and during HIV-1 infection these levels have been show to correlate with the 
depletion of the CD4 T cell population (11, 12). In this work, it was showed for the first time, 
a strong inverse correlation between circulating IL-7 levels and the degree of CD4 T cell 
depletion in HIV-2 infection (9).   
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In the periphery, the mechanisms that drive increased circulating IL-7 levels remain unclear 
(13, 14). As it was previously proposed, elevated circulating IL-7 levels could result from an 
increased homeostatic response to the CD4 lymphopenia (11, 13, 15). On the other hand, the 
circulating IL-7 levels may increase as a result of its diminished binding and internalization 
by a reduction in the number of cells expressing the IL-7Rα (14, 16). The findings described 
here showing that in early stages of HIV-2 infection, the levels of circulating IL-7 were not 
significantly increased as compared to healthy cohort, and a much better preservation of the 
levels of IL-7Rα expression in the naive CD4 T cells than in HIV-1 infection, support the 
latter possibility. Thus, the delayed increase in circulating IL-7 levels throughout HIV-2 
disease may result from the sustained expression of IL-7Rα, which suggests a maximization 
of available resources to allow the survival of the naive CD4 T cell population.  
 
Interestingly, in early HIV-2 infection, circulating IL-7 levels were not only lower that in 
HIV-1 but also similar to the healthy cohort. To better interpret these results it would be 
relevant to understand how the HIV-2 infection is established. There are no clinical reports of 
HIV-2 acute infection and no available data on lymph node or mucosal pathology during 
HIV-2 disease. However, it is reasonable to speculate that the establishment of HIV-2 
infection may not be associated with a high viremia peak and with a major depletion of the 
memory compartment. Recent data on acute HIV-1 infection, show a marked depletion of 
CD4 T cell subsets mainly in the gut, that persist throughout disease (17-19).  It is plausible 
that the early depletion of this cell population significantly contributes to the higher 
circulating IL-7 levels. The possible contribution of gut-associated CD4 depletion in 
triggering the early increase of IL-7 production in HIV-1 infection that was not observed in 
HIV-2 infection deserves further exploration.  
 
IL-7 is a key cytokine in T cell homeostasis in the periphery by promoting T cell proliferation 
and survival, particularly of the naive CD4 and CD8 T cell pools (12, 13, 20- 23). In HIV-1 
infected patients, IL-7 was shown to mediate survival and expansion of naive and memory T 
cell populations and inhibits apoptosis of CD4 and CD8 T cells in vitro (24). 
Recently, our lab showed that IL-7 preferentially induces proliferation of the CD31+ naive 
CD4+ T cell subpopulation in both adult peripheral blood cells and cord blood cells, with the 
maintenance of CD31 expression in vitro (25). The CD31+ subset of naive CD4 T cells is 
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thought to be enriched in recent thymic emigrants (RTE) as described in the introduction of 
this work (26). Therefore, these data suggests that RTE in the naive T cell subset are more 
likely to respond to IL-7 by increasing their rate of homeostatic proliferation and still 
preserve RTE phenotype. 
 
IL-7 therapy has been suggested to be a good candidate for inducing immune reconstitution 
in lymphopenic diseases. In T cell lymphopenic murine models, exogenous IL-7 
administration or IL-7 transgenic over expression results in marked increases of naive CD4 
and CD8 T cell numbers (27-29). In non-human primates exogenous IL-7 induces the 
expansion of naive peripheral T cells and enhanced de novo thymic production in SIV-
infected animals (30-32). Several phase I/IIa clinical trials designed to assess the safety of 
administration of recombinant human IL-7 (rhIL-7) to humans, show absent or very low 
significant drug toxicity (33-35). Phase I studies of rhIL-7 therapy for HIV-1 infected patients 
showed a sustained increase in the naive CD4 and CD8 subsets (33, 34) with a transient 
expansion of RTE defined as CD4+CD45RA+CD31hi
 
 (34). Also, phase I studies of 
administration of rhIL-7 in patients with refractory cancer, showed a sustained increase in 
peripheral blood CD4 and CD8 T cells with a preferential expansion of RTE, and a 
broadening of TCR repertoire diversity measured by spectratyping (35). 
These results suggest that rhIL-7 therapy, in combination with efficient antiretroviral therapy 
(ART), can increase the naive T cell pool, by enhancing peripheral proliferation with 
maintenance of naive phenotype. Additionally, a possible contribution of rhIL-7 therapy in 
the enhancement of thymopoiesis should be considered, as Beq et al showed for SIV infected 
macaques treated with IL-7 (30). Most likely it is a combined effect of enhanced 
thymopoiesis and naive peripheral expansion. Thus, these data suggested that rhIL-7 therapy 
could enhance and broaden immune responses, particularly in patients with limited naive T 
cells and diminished TCR repertoire diversity.  
 
Importantly, rhIL-7 therapy showed a sustained increase in the central memory CD4 and CD8 
T cell subsets with a transient increase in cell cycling and activation markers (33, 34). These 
expanded CD4 and CD8 T cells responded in vitro to TCR stimulation by proliferating and 
producing intracellular cytokines (34). Of note, exogenous IL-7 augments effector and 
memory responses to vaccination in animal studies and IL-7 therapy augments antitumor 
responses, leading to improved survival when combined with antitumor vaccines (36, 37). 
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On the other hand, IL-7 is a strong inducer of HIV-1 replication in vitro (38-40), leading to 
its proposed use as a therapy to purge the viral reservoirs in HIV-1 infected patients on ART 
with evidence of sustained suppression of circulating viral load (38). Importantly, in both 
communications of rhIL7 administration to HIV-1 infected patients with ART suppressed 
viral load, there were no described cases of sustained elevation of the viremia during rhIL-7 
therapy (33, 34). However, 4 patients treated with higher dosages of rhIL-7 presented “blips” 
or intermittent elevations of the viral load that returned to basal levels (34). Of note, none of 
these studies were designed to address the impact of rhIL-7 therapy on the viral reservoirs on 
quiescent T cells. Other reports of SIV infected macaques treated with IL-7 also showed no 
increase in viral load (41). Thus, more data is necessary to really evaluate the effect of rhIL-7 
therapy in viral purging, including the possible dosage adjustments required to achieve an 
effective reduction in the pool of latently infected cells. 
 
Although there are no data on the ability of IL-7 to promote HIV-2 replication, it would be 
expected to be comparable given the similarity of the two viral promoter regions (LTRs) (42). 
It would be very important to clarify this issue given the low to undetectable HIV-2 viremia 
documented, in spite of the presence of HIV-2 proviral DNA levels in the range of those 
found in HIV-1 infection (43-45) and the high circulating IL-7 levels in advanced disease 
stages (9).   
 
The Thymus in HIV/AIDS Pathogenesis 
 
The impact of a functional thymus on HIV progression has not been fully established in part 
due to the difficulty in assessing thymic function or lack thereof, directly in infected patients.  
 
Importantly, Dion et al proposed a marker for measuring thymic function, by estimating the 
intrathymic proliferation history of peripheral lymphocytes based on the quantification of the 
sj/β TREC ratio (6, 8, 46). Using this technique Dion et al (6), showed suppression of 
intrathymic proliferation in HIV-1 infected patients in the initial phase of disease. The data 
presented here showed for the first time that HIV-2 infected patients have elevated sj/β TREC 
ratios, suggesting a maintained thymic production throughout HIV-2 disease. Moreover, in 
HIV-2 infected patients, the sj/β TREC ratios were maintained independent of age as opposed 
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to the healthy controls that presented an age dependent reduction in the sj/β TREC ratios, in 
parallel with the expected thymic involution (10). 
 
Thus, the data presented are compatible with a thymic preservation or rebound in HIV-2 
infected patients, possibly contributing to the sustained replenishment of the naive T cell pool 
and to the slower rate of CD4 decline that distinguishes HIV-2 from HIV-1 infection. In 
agreement, in HIV-1 infected patients with a slower rate of disease progression, it was 
demonstrated that the maintenance of circulating CD4 T cells is strongly associated with 
efficient thymopoiesis (46).  
 
However, there are no data on the direct impact of HIV2 infection on the thymus. It would be 
important to further investigate the impact of HIV-2 infection on the thymus, in particular to 
determine if the different thymocyte populations are permissive to HIV-2 infection and 
replication. Furthermore, it would relevant to investigate the impact of HIV-2 on T cell 
development and on CD34+
 
 progenitor differentiation, which have been shown to be 
compromised during HIV-1 infection (47). 
The maintenance of thymic activity and naive T cell homeostasis is considered fundamental 
for the development and preservation of a broadly diverse T cell repertoire in the periphery. 
This is thought to be critical for the organism to maintain the ability to mount responses to 
new pathogens, prevent relapsing of latent microorganisms and delay disease progression in 
persistent infections.  
 
Thus, in order to study thymic function it is of great importance to quantify the diversity of 
the TCR repertoire. This has not been formally addressed due to limitations of the 
methodologies currently available to measure diversity. It would be very relevant to find a 
good reliable technique that measures TCR repertoire diversity in order to have a reliable 
measurement of thymic function.  
 
The current mostly used approach devised to do so, immunoscope or spectratyping, is based 
on the fact that during rearrangement of the α and β regions of the TCR, nucleotides are 
incorporated to increase diversity of segments between the VDJ regions. Given that this is a 
random process, the quantification of the nucleotides incorporated in the CDR3 regions in all 
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the T cells should follow a Gaussian curve, as reported in samples from healthy individuals. 
In the presence of a skewed repertoire, due to manipulation or disease, the curves of the 
CDR3 are non-Gaussian in shape, since not all the possible CDR3 lengths exist in a 
contracted repertoire (48). However in the context of HIV pathology this methodology should 
be used with caution, due to the possible oligoclonal expansions associated with T cell 
responses to antigens, both from HIV or other opportunistic infections. Thus, the skewing of 
the Gaussian curve in a sample of T cells from an HIV infected patient may not be related to 
the disruption of thymic function but to clonal expansions and relative imbalances of T cell 
subpopulations represented in the assessed sample.   
 
Therefore, a reliable method that quantifies the diversity of the TCR repertoire with adequate 
sensitivity to detect and identify minor changes and/or clonal expansions is still critically 
necessary, despite promising recent approaches (49). Such an assay could be very important 
not only to the understanding of HIV/AIDS pathology but also for the evaluation of 
immunodeficiencies and immune reconstitution in general. 
 
Final remarks  
 
In conclusion, the overall objective of this work was to contribute to the better understanding 
of mechanisms and implications of HIV mediated loss of thymic function and impaired T cell 
homeostasis, through the use of an attenuated natural model of HIV disease, the HIV-2 
infection.  
 
The data discussed here point to a better maintenance of thymopoiesis and peripheral use of 
IL-7 during HIV-2 infection. Devising ways to improve these parameters in HIV-1 infected 
patients in conjunction with ART may contribute to a better outcome and an improvement in 
the quality of life of the people affected by this disease.  
 
HIV1 infection has been under study for the past 26 years and every piece of evidence is a 
small stone in the path of understanding and finding effective therapy options and 
prophylactic approaches. 
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PART II  
 
TACI REGULATION OF B CELL DIFFERENTIATION 
AFTER ANTIGENIC STIMULATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“I am among those who think that science has great beauty. A scientist in his laboratory is 
not only a technician: he is also a child placed before natural phenomena which impress him 
like a fairy tale.” Marie Curie 
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Deficiencies in the Transmembrane Activator and Calcium Modulating Cyclophilin Ligand 
Interactor (TACI) receptor are associated with Common Variable Immunodeficiency (CVID) 
in humans (1, 2). CVID is a primary immunodeficiency that comprises a heterogeneous 
group of diseases with deficient immunoglobulin (Ig) production (3-6). It is the most 
prevalent human primary immunodeficiency with clinical expression, affecting 1 in 25,000 
Caucasians (7, 8); 5% to 10% of subjects with CVID carry at least one germline mutation in 
the TACI locus (1, 2, 9). 
 
TACI deficiency causes recurrent bacterial infections, particularly of the respiratory tract (1, 
2, 10) and impaired responses to vaccination against encapsulated bacteria such as 
Streptococcus pneumoniae or Haemophilus influenzae (2). The impaired clearance of 
encapsulated bacteria in TACI deficient subjects has been attributed to reduced IgG and IgA 
production owing to a B cell defect. In support of a primary B cell defect, Salzer et al (1) 
showed that some TACI deficient subjects have decreased number of CD27+
 
 antigen 
experienced B cells. How TACI promotes antibody production is not understood and the 
subject of the second part of this work. 
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TACI deficiency in humans and in mice 
 
Recently, mutations in the human TACI locus were found in 5% to 10% of patients 
diagnosed with Common Variable Immunodeficiency (CVID) (1, 2). Individuals with CVID 
exhibit deficient production of antibodies of all isotypes (1, 2). Because most CVID subjects 
have relatively normal numbers of B lymphocytes, defective Ig production is thought to 
reflect defective activation and differentiation of B cells. (3, 11). Consistent with this idea, 
plasma and memory B cells are reduced (8, 12-14). Also, individuals with CVID suffer from 
recurrent otitis and sino-pulmonary infections typically due to encapsulated bacteria such as 
Haemophilus influenza and Streptococcus pneumoniae (5, 6). CVID also causes increased 
incidence of autoimmune disorders and of lymphoid and nonlymphoid malignancies (8, 12, 
15). 
 
Several point mutations in the TACI locus, TNFRSF13B, have been described and are 
depicted in Figure 1. The most commonly found, C104R or A181E, do not abolish 
expression; in contrast, S144X, S194X and an insertion, 204insA, result in decreased or 
abolished expression (16, 9, 17). In one recent study (16) Salzer et al found that all patients 
with biallelic mutations had hypogammaglobulinemia. In another study, patients with 
monoallelic changes in TNFRSF13B
 
 and heterozygosity for the most common TACI 
mutation, C104R, had antibody deficiency, suggesting that some mutated TACI proteins 
exert dominant negative functions (9, 17).  
TACI deficient mice mount deficient IgG antibody responses to polysaccharides and have 
decreased serum IgA and IgG (18). Defective antibody responses by TACI-deficient mice 
were not owed to decreased B cells since TACI-deficient mice have more B cells than wild-
type mice, including more marginal zone B cells (IgM+IgD-CD21+) and B1 B cells 
(CD5+IgM+ B cells, present mainly in the peritoneal cavity) which are thought to contribute 
most of the antibodies to polysaccharides. Thus, TACI deficiency does not appear to impair 
the development or maintenance of polysaccharide-responsive B cells in mice (18). In fact, 
Yan et al. (19) showed that TACI deficient B cells hyperproliferate in response to 
lipopolysaccharides (LPS) and that TACI deficient mice develop splenomegaly and enlarged 
lymph nodes (18), suggesting that TACI may inhibit B cell proliferation. Thus TACI 
deficiency may on one hand be a B cell co-receptor necessary to evoke anti-polysaccharide 
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responses (18), and on the other hand inhibit B cell proliferation (19, 20). How TACI 
combines inhibitory and stimulatory B cell functions is not understood.   
 
There are several differences in the phenotypes associated with TACI deficiency in humans 
and in mice. While TACI deficient mice have increase number of  B cells, human subjects 
with TACI deficiency have normal or slightly reduced number of B cells including decreased 
CD27+
 
 memory B cells in the blood of most patients (1, 16). In TACI deficient mice there is 
a reduction mostly in IgG and IgA subclasses while in human subjects TACI deficiency all 
isotypes are reduced (2). Both mice and human subjects with TACI deficiency have impaired 
responses to vaccination against Pneumococcus indicating defective antibody production to 
polysaccharide antigens (2). While TACI deficient mice develop systemic lupus 
erythematosus, TACI deficient subjects develop mostly other autoimmune diseases such as 
Graves disease, pernicious anemia, rheumatoid arthritis, Sjogren’s, hemolytic anemia with 
idiopathic thrombocytopenic purpura (5). Autoimmune manifestations may not be a direct 
cause of TACI deficiency since these manifestations also occur in individuals with CVID due 
to mutations in genes other than TACI (21). 
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A            B  
 
  
Figure 1 – (A) Summary of mutations in the TACI locus, TNFRSF13B, that have been described 
to date in CVID patients. (B) Schematic representation of TACI structure and ligand dependent 
recruitment of intracellular signaling (CAML, TRAFs) by TACI ligands (APRIL, BAFF).  
Adapted from Castigli, et al (17).  
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TACI intracellular signaling and ligand interactions 
 
TACI is a type III transmembrane protein receptor, with a structure typical of the tumor 
necrosis factor (TNF) receptor superfamily (Reviewed in (22, 23)). In humans TACI is 
expressed by marginal zone B cells and by CD27+
 
 memory B cells (24, 25) and TACI 
expression is enhanced after B cell stimulation (26), whereas murine TACI is constitutively 
expressed by all B cells and activated T cells (24, 27). B cells produce two TACI alternative 
splicing variants with extra-cellular N-terminal domains with one or two cysteine-rich 
domains (CRDs) that include a conserved six-residue motif, (F/Y/W)-D-x-L-(V/T)-(R/G) 
required for ligand binding and receptor activation (28, 29). 
TACI has two known TNF-like ligands that bind with high affinity, B cell activating factor 
(BAFF, also known as BLyS) (30-33) and a proliferation inducing ligand (APRIL) (34-36). 
APRIL and BAFF share several features, both are synthesized as type II transmembrane 
proteins with a TNF homology C terminal domain and are proteolytically cleaved into 
soluble form at a multibasic motif by a furin-like protease (37); both are expressed in 
monocytes-macrophages and dendritic cells (38) and BAFF is also expressed by neutrophils 
(39). BAFF and APRIL also bind to B cell maturation antigen (BCMA) receptor (35) and 
BAFF binds to B cell activating factor receptor (BAFF-R) (40). TACI is the only receptor 
that binds BAFF/APRIL heterotrimers (28, 41). Bischof and collaborators (42) showed that 
TACI also binds to syndecan-1, -2 and -4, membrane-bound proteoglycans that contain large 
extracellular domains with heparan-sulfate post-translational modifications. In contrast to 
BAFF and APRIL, syndecans bind only TACI and not BAFF-R or BCMA as illustrated in  
Figure 2 (42). 
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Figure 2 – Representation of TACI and its ligands, BAFF and APRIL and their receptors, 
BCMA and BAFF-R.  
TACI is the only receptor that binds BAFF/APRIL heterotrimers (28, 41). APRIL and TACI also bind 
to membrane-bound proteoglycans that contain large extracellular domains with heparan-sulfate post-
translational modifications. (42). Adapted from Castigli, et al (43). 
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TACI receptor activation initiates two signal transduction pathways. In one, TACI recruits 
TNF receptor associated factors (TRAF) 2, 5 and 6 (44), and in another TACI binds the 
calcium modulating cyclophilin ligand (CAML) as depicted in Figure 3 (27).  
 
TRAF 2, 5 and 6 activate nuclear factor kappa B (NF-κB) (44, 45) and c-Jun NH2-terminal 
kinase (JNK). Activation of NF-κB and JNK control many steps in the differentiation of B 
cells, including proliferation, class switch recombination and plasma cell differentiation (46-
48) but because these pathways can be activated by many different receptors their function 
does not uniquely reflect activation of TACI.  
 
TACI binds to CAML (27), and the TACI-CAML binding activates phospholipase C-γ (PLC-
γ), which hydrolyses phosphatidylinositol-4,5-bisphosphate to produce inositol-1,4,5-
trisphosphate (InsP3) and diacylglycerol. InsP3 induces the release of calcium from 
intracellular stores. Calcium binds calmodulin, which in turn activates the calmodulin-
dependent phosphatase, calcineurin (49). Nuclear factor of activated T cells (NFAT) proteins 
are then dephosphorylated by activated calcineurin, which leads to their nuclear translocation 
and the induction of NFAT-mediated gene transcription as recently reviewed by F. Macian  
(50). TACI-CAML interactions promote translocation of the transcription NFAT to the cell 
nucleus, because NFAT translocation is specifically blocked by a dominant-negative CAML 
mutant (27, 51). 
 
In the nucleus, NFAT interacts with activator protein 1 (AP-1) to promote transcription of 
genes that encode transcription factors, signaling proteins, cytokines, cell surface receptors, 
and other effector proteins, as reviewed by Rao et al (52). In B cells, AP-1 represses B cell 
lymphoma 6 (BCL-6), a transcriptional repressor protein (53, 54). Repression of BCL-6 is 
necessary to drive differentiation of plasma cells through the expression of B lymphocyte-
induced maturation protein-1 (Blimp-1) (55). It is possible that TACI deficient B cells 
differentiate poorly into plasma cells owing to incomplete activation of AP-1.  
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Figure 3 – Schematic representation of signaling pathways downstream of BAFF receptors.  
The molecular events that lead to B cell survival, Ig swich or other responses downstream of BAFF-
R, TACI (highlighted) or BCMA are poorly characterized. Adapted from Bossen, et al (22). 
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The phenotype caused by TACI deficiency may be owed to the lack of receptor function but 
also to the compensatory changes associated with the increased availability of ligands to bind 
the BAFF-R and BCMA. Thus, defective antibody responses to polysaccharides in TACI 
deficient mice are not due to deficient APRIL signaling since APRIL-deficient mice have 
normal antibody responses to polysaccharides (56). However over-expression of APRIL 
enhances antibody responses to polysaccharides (57) presumably by activating TACI since 
BCMA is dispensable for antibody responses to polysaccharides (58). BCMA promotes 
antibody production in response to proteins possibly by enhancing plasma cell survival (59). 
IgA production may require the binding of APRIL to TACI (60) with the exclusion of other 
ligands or receptors because APRIL deficient mice, as TACI deficient mice, show a selective 
deficiency of IgA (61).  
 
TACI deficiency increases the B cell compartment (18-20) which is consistent with an 
increased availability of BAFF to bind the BAFF-R. Administration of BAFF to mice 
increased the number of B cells (62) and conversely, lack of BAFF in mice severely 
contracted the B cell compartment  and reduced antibody responses (63, 64) indicating that 
BAFF controls B cell homeostasis.  
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Aim  
  
TACI appears to have both inhibitory and activating roles in B cell differentiation; on one 
hand, TACI inhibits uncontrolled B cell proliferation; on the other promotes B cell 
differentiation and Ig isotype class switch mostly in response to polysaccharide antigens.  
How TACI accomplishes such distinct responses was the main objective of this work.  
 
To determine the origin of the antibody deficiency caused by TACI deficiency, TACI KO 
mice were bred with Quasi-Monoclonal (QM) mice that are genetically engineered to 
produce a contracted antibody repertoire. The Quasi-Monoclonal mouse (QM) was 
engineered by Cascalho et al (65) as a model for studying the generation of antibody 
diversity. In QM mice, 80% of the peripheral B cells express a BCR encoded by a knock-in 
VH17.2.25 heavy chain and the λ1 or λ2 L chain that binds to a hapten, 4-hydroxy, 3-nitro-
phenylacetic acid (NP) and its derivatives. These mice mount enhanced responses to 
polysaccharide-like antigens such as NP conjugated to Ficoll owing to increased antigen-
specific marginal zone B cells (IgM+ IgD- CD21+
 
) (66). Marginal zone B cells are thought to 
constitute the first line of response to encapsulated microbes.  
Thus, QM TACI KO mice immunized with NP-Ficoll, a polysaccharide like T-independent 
antigen, were studied, the frequencies of antibody secreting B cells were measured and the 
amount of antibodies produced was quantified, in order to clarify the mechanism by which 
TACI controls antibody responses to polysaccharides. 
 
This part of the work was done at the Transplantation Biology Program, Mayo Clinic, under 
the close supervision of Dr Cascalho and in collaboration with Dr. Bram’s lab (Mayo Clinic). 
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Abstract 
 
The control of systemic infection by encapsulated microorganisms requires T-independent 
type II (TI-2) antibody (Ab) responses to bacterial polysaccharides. To understand how such 
responses evolve, we explored the function of transmembrane activator calcium modulator 
and cyclophilin ligand interactor (TACI), a member of the TNFR family, required for TI-2 
Ab production. Quasimonoclonal (QM) mice produce robust TI-2 responses to 4-hydroxy-3-
nitrophenylacetate (NP)-Ficoll, owing to the high precursor frequency of NP-specific B cells 
in the marginal zone of the spleen. QM mice that lack TACI produce decreased numbers of 
IgM (2-fold) and IgG (1.6-fold) NP-specific antibody-secreting cells (ASCs) compared with 
TACI-positive QM mice in response to immunization with NP-Ficoll. Our studies indicate 
that TACI acts at a remote time from activation because TACI is not necessary for activation 
and proliferation of B cells both in vitro and in vivo. Instead, TACI-deficient QM B cells 
remained in the cell cycle longer than TACI proficient QM cells and had impaired plasma 
cell differentiation in response to NP-Ficoll. We conclude that TACI has dual B cell-
autonomous functions, inhibiting prolonged B cell proliferation and stimulating plasma cell 
differentiation, thus resolving the longstanding paradox that TACI may have both B cell-
inhibitory and -stimulatory functions. By promoting plasma cell differentiation earlier during 
clonal expansion, TACI may decrease the chances of autoantibody production by somatic 
hypermutation of immunoglobulin (Ig) genes in response to T-independent antigens (Ags). 
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T-independent type II antigens (TI-2 Ags) are large polysaccharides found in the capsules of 
such bacteria as Streptococcus pneumoniae, Haemophilus influenza and Klebsiella 
pneumoniae. These capsular polysaccharides do not activate the lectin or alternate pathways 
of complement; hence, activation of the classical pathway by antibodies (Abs) is required for 
effective opsonization (1). Humans with impaired ability to mount Ab responses to 
polysaccharides, including young children and splenectomized adults, are at increased risk of 
life-threatening infections from encapsulated bacteria (2). 
 
To study Ab responses to polysaccharides we took advantage of the quasi-monoclonal (QM) 
mice. In the QM mice 80% of the peripheral B cells express a BCR encoded by a knock-in 
VH17.2.25 heavy (H) chain and the λ1 or λ2 light (L) chain (3). These mice mount enhanced 
responses to 4-hydroxy-3-nitrophenylacetate (NP)-Ficoll (a TI-2 Ag), owing to an increased 
B cell precursor frequency with a marginal zone phenotype (IgM-positive, IgD-negative and 
CD21-positive) (4). The marginal zone B cells are thought to constitute the first line of 
response to encapsulated microbes (5).   
 
What special properties of B cells besides the B cell receptor (BCR) may allow TI-2 
responses to occur is not known. We explored the functions of the trans-membrane activator 
calcium modulator and cyclophylin ligand interactor (TACI), found previously to be needed 
to mount effective TI-2 Ab responses (6). TACI has two known ligands: B lymphocyte 
stimulator (BLyS) and the proliferation inducing ligand (APRIL). Administration of BLyS to 
mice increased B cell numbers and enhanced Ab responses to both T-dependent Ags and TI-2 
Ags (7). Conversely, mice that lack BLyS had severely reduced B cell numbers and reduced 
Ab responses (8). In contrast, APRIL knockout (KO) mice have normal TI-2 responses (9), 
but transgenic expression of APRIL led to increased TI-2 Ab responses (10).   
 
BLyS and APRIL bind to two other receptors B cell activating factor receptor (BAFF-R) and 
B cell maturation Ag (BCMA) in addition to TACI. BCMA promoted plasma cell survival in 
T-dependent responses (11) but was dispensable for TI-2 Ab responses (12); mutations in the 
intracellular domain of BAFF-R (A/WySnJ mice) caused reduced Ab responses to both TI-2 
Ags and T-dependent Ags and decreased numbers of peripheral B cells (13). Thus, 
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contribution of TACI for TI-2 Ab responses in response to BLyS and APRIL remains 
unclear. Previous work by the authors revealed that TACI binds uniquely to heparan sulfate 
post-translational modifications of syndecan-2 (14). Thus, some of the unique functions of 
TACI may be attributed to binding of TACI to heparan sulfate on syndecan-2.  
 
Mice lacking TACI are unable to mount effective TI-2 Ab responses (6), suggesting that 
TACI is needed for the generation of these responses. How TACI promotes these responses is 
not known. TACI-KO mice have increased numbers of all B cell subtypes (6), including 
marginal zone B cells (15) and B1 B cells (16), suggesting that TACI deficiency does not 
impair the development of polysaccharide-responsive B cells. This contrasts with models 
with defective TI-2 Ab responses, owing to decreased or absent B cells in the marginal zone 
of the spleen or in the serosal cavities (B1 B cells). In contrast to the apparent impact on TI-2 
responses, TACI is thought to inhibit some B cell functions. Thus, TACI-/- B cells hyper-
proliferate in response to polyclonal activators in vitro, and loss of TACI causes 
autoimmunity in mice (6, 17, 18), suggesting that TACI is a B cell inhibitory receptor. How 
TACI combines inhibitory and stimulatory B cell functions is not understood. Here we asked 
whether TACI regulates B cell differentiation following T-independent stimulation of B cells. 
 
To determine the mechanism by which TACI controls TI-2 Ab responses, we bred TACI-KO 
mice with the QM mouse (3) to obtain TACI-negative QM mice. Because in QM mice the 
transgenic heavy chain was targeted into the JH locus, it can undergo isotype switching and 
somatic hypermutation. We studied how TACI promotes QM B cell responses to NP-Ficoll (a 
TI-2 Ag). We found that QM B cells lacking TACI are normally activated by Ag but 
proliferate longer and have impaired plasma cell differentiation. Our findings suggest that 
TACI acts remotely from B cell activation and provides a critical signal for cells to exit the 
cell cycle and to differentiate into plasma cells.  
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Materials and Methods 
 
Mice and Immunizations: 
TACI-KO and QM mice were previously described (3, 6). TACI-KO mice were bred to QM 
mice and are in a C57BL/6 (B6) background. Animals were bred and treated according to the 
policies of Mayo Foundation Institutional Animal Care and Use Committee. Mice were 
immunized with 30 µg intra-peritoneally (i.p.) of NP-Ficoll (NP41-AECM-Ficoll, Biosearch 
technologies) diluted in sterile PBS. 
 
Isolation of primary B cells: 
CD19+
 
 splenocytes were isolated by negative selection with a B cell isolation kit (Miltenyi 
Biotec), as per the manufacturer’s protocol. Cells were grown in RPMI-1640, 10%FCS, 
1%v/v Pen/Strep, 55 µM 2-ME.  
ELISA: 
NP-specific Abs in the sera were determined using ELISA, as previously described (19).  
 
ELISPOT: 
Multiscreen HTS-HA 96 well plates purchased from Millipore were coated with 5 µg/ml NP-
BSA or 5 µg/ml BSA in sodium carbonate buffer overnight at 4oC. Plates were blocked with 
5% milk in TBS-Tween, and B cells obtained by negative-selection with magnetic miltenyi 
microbeads (MACS) were serially diluted from a maximum of 2x105 or 5x105 cells per well, 
and cultured overnight. ELISPOTS from splenocytes isolated from adoptively transferred 
mice were not further processed because recipient mice lack T cells and were transferred with 
isolated B cells. Ab secreting cells (ASCs) were detected with AP-conjugated goat anti-
mouse IgM or IgG Ab (Southern Biotech) for 2 hrs at 37o
 
C. The plates were developed with 
5-bromo-4-chloro-3-indolyl phosphate-NBT substrate (SigmaFast, Sigma Co), and dots 
counted by microscopy. 
Thymidine incorporation: 
Splenocytes or negatively selected B cells isolated using MACS B cell isolation kit (Milteny 
Biotec) were plated at concentration 1x106 cells /ml and stimulated with NP-Ficoll or LPS at 
the concentrations shown. At 72 h after the stimulation, 1 µCi [3H]TdR (MP Biomedicals) 
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per well was added for an additional 16-20 h. At the end of the culture period 50-60% of cells 
were viable as determined by trypan blue exclusion. Cells were lysed by hypotonic lysis, 
transferred to glass fiber filters (Packard) and counted on Matrix96-Direct Beta Counter 
(Packard). 
 
Adoptive transfer: 
Ten million negatively selected B cells isolated with the B cell isolation kit (Milteny Biotec) 
were injected into the jugular vein of RAG1-/- on B6 background 1 h before immunization. 
 
FACS staining: 
Biotinylated anti-idiotypic Ab (R2.438.8) directed against the QM Ab (17.2.25 monoclonal) 
was a generous gift from Dr. Imanishi-Kari (Tufts University). All other Abs were purchased 
from BD Pharmingen. FITC-conjugated mAbs were anti-mouse CD21 (7G6), IgDa 
(AMS9.1), GL7 and B220 (RA3-6B2). PE-conjugated mAbs were anti-mouse CD23 (B3B4), 
IgMa (DS-1), CD138 (281-2) and FAS (CD95). Biotynilated mAbs were anti-mouse IgDa 
(AMS9.1) and CD138 (281-2). Allophycocyanin-conjugated mAbs were anti-mouse CD19 
(ID3) and B220 (RA3-6B2). Peanut aglutinin (PNA) was biotynilated (Vector Laboratories). 
Biotynilated Abs were revealed by streptavidin-PE-Cy5 purchased from BD Pharmingen. 
Data was collected using FACScan or FACSCalibur and analyzed with Cellquest software. 
For Annexin V binding assay, the cells were first stained with Abs directed to surface Ags 
and later stained with AnnexinV-PE Apoptosis Detection kit 1 (BD Pharmingen) according to 
the manufacturer’s recommended protocol. Cell cycle analysis was done according to 
previously described procedures (20) in isolated B cells. 
 
 174 
 
Part II – Results  
Results  
 
TACI deficiency compromises IgG TI-2 Ab production and formation of ASCs in QM mice  
 
To explore the involvement of TACI in TI-2 Ab responses, we bred TACI-KO mice(TACI-/-) 
with QM mice that have enhanced TI-2 responses to NP-Ficoll, in part owing to increased 
marginal zone NP-specific B cells (4). QM TACI-/- mice had 2.3-fold more splenocytes and 
B cells than QM TACI +/+ mice (Figure 1a). The increase in the number of B cells in QM 
TACI-/- mice did not alter the proportions of naive (IgM+ IgD+, 51% in TACI-/-versus 43% 
in TACI+/+), marginal zone(CD21+++, CD23+, 42% in TACI-/- versus 44% in TACI+/+) or 
follicular(CD21+, CD23+++
QM mice respond vigorously to NP-Ficoll, a TI-2 stimulus, by producing NP-specific IgM 
(3246 µg/ml) and IgG3 (9.0 µg/ml) in the serum 4 days after immunization. QM mice 
deficient in TACI produced only 1.6 µg/ml NP-specific serum IgG3, 5.6-fold less than TACI-
positive QM littermates, and comparable levels of NP-specific serum IgM (2673 µg/ml) 
indicating that TACI promotes IgG3 production in response to TI-2 stimuli in QM mice. 
, 31% in TACI-/- versus 32% in TACI+/+)B cells (Figure 1b).  
 
Next, we asked whether TACI was required to produce QM ASCs in the spleen following 
immunization with NP-Ficoll. The number of NP-specific ASCs was determined by 
ELISPOT 6 days after immunization. TACI-negative QM mice showed 2-fold decreased 
numbers of IgM and 1.6 fold-decreased numbers of IgG NP-specific ASC per spleen, 
compared to TACI-positive QM mice (Figure 2a). The number of IgM or IgG ASCs in the 
bone marrow was also decreased albeit not significantly, by 1.8- and 1.2-fold respectively, in 
TACI-negative mice compared to TACI-positive QM mice. Analysis of spleen sections 
showed that the number of B cells that differentiated into plasma cells (CD138+) peaked at 
day 6 and slowly decreased thereafter (not shown).  The number of plasma cells in the 
perifollicular areas of the spleen was significantly decreased in TACI-negative compared to 
TACI-positive QM mice 6 days after immunization (Figure 2b). Given that the precursor 
frequencies of NP-specific B cells were the same in TACI-negative QM and TACI-positive 
QM mice (approximately 85% for both, data not shown), our findings of reduced splenic 
ASC in QM mice deficient in TACI indicate that TACI promotes terminal differentiation. 
Decreased numbers of plasma cells were not due to increased apoptosis in TACI-negative 
QM mice, because TACI-negative CD138+ cells had reduced apoptosis (Figures 3e and 3f), a 
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finding consistent with published reports indicating that an EDAR-TACI fusion induces 
death in the A20 mouse plasma cell line (17).  
 
 
 
A      B 
 
 
 
 
 
 
 
Figure 1. QM TACI-deficient mice have an increased number of B cells in the spleen and 
maintained marginal zone (MZ)/follicular B cell subset distribution.   
Splenocytes from QM mice (QM, n=3) or QM-TACI– (KO) littermates (n=3) were counted and 
analyzed by flow cytometry. (A) Numbers of splenocytes and CD19+ B cells in QM or QM-TACI– 
mice (KO), as indicated. The number of B cells was calculated by multiplying the fraction of CD19+ 
B cells identified by FACS by the number of splenocytes. QM mice had, on average, 37+/-15 million 
splenocytes and 11+/-5 million B cells; QM-TACI– mice had, on average, 84+/-7 million 
splenocytesand 24+/-3 million B cells. *, Significant differences. (B) Flow cytometry analysis of 
splenocytes. A typical plot is shown (from three independent experiments). Plots were obtained by 
gating on the lymphocyte gate defined on light scatter plots and on CD19+ cells. y-axis, fluorescence 
intensity of splenocytes stained with anti-mouse IgM or anti-mouse CD23 Abs PE-conjugated; x-axis, 
fluorescence intensity of splenocytes stained with anti-mouse IgD- or anti-mouse CD21 Abs FITC-
conjugated, as indicated. 
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Figure 2.  TACI deficiency leads to impaired antibody-secreting cell (ASC) formation after TI-2 
immunization.   
(A) The number of IgM or IgG ASCs was determined by NP-ELISPOT of B cells purified from the 
spleen or bone marrow 6 days after i.p. immunization of QM or QM-TACI-KO mice (n=5 mice per 
cohort) with 30 µg of NP-Ficoll. TACI– mice had only 564 IgM or 33 IgG ASCs whereas TACI+ 
mice had 2579 IgM or 125 IgG ASC per 500,000 B cells from the spleen. After correction for the 
increased number of B cells in the spleen of TACI– mice, our results indicate that TACI deficiency 
causes a 2-fold decrease in the absolute number of IgM-producing cells and 1.6-fold decrease in the 
number of IgG producing cells in the spleen, 6 days after immunization. TACI– mice had 318 IgM or 
6.3 IgG ASCs, whereas TACI+ mice had 584 IgM or 7.7 IgG ASC per 500,000 B cells in the bone 
marrow. *, Significant differences. (B) Spleen frozen sections obtained on day 6 after immunization, 
stained with anti-CD138 Abs to detect plasma cells. Image shows reduced accumulation of plasma 
cells in the perifollicular areas in TACI– mice. Images are representative of images obtained from 
three independent experiments. 
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TACI deficiency causes B cells to remain proliferating longer and to differentiate less after 
TI-2 Ag stimulation in vivo 
 
We next tested whether TACI promotes B cell differentiation early or late relative to B cell 
activation. We first determined if TACI deficiency enhances QM B cell proliferation by 
calculating the relative number of CD19+ cells in the G2-S and M stages of the cell cycle after 
immunization. Figure 3a shows that 6 days after immunization there were more TACI-
negative QM B cells cycling (in G2-S or M stages of the cell cycle, 9.6% on average), 
compared with TACI-positive B cells (5.9%, on average). Curiously, the number of TACI-
positive and TACI-negative B cells cycling 4 days after immunization is similar, suggesting 
that TACI is necessary at a time remote from activation, thus limiting clonal expansion. 
Figure 3a also shows that the number of cycling B cells was greater in non-immunized mice 
(2-fold in TACI-positive mice and 1.6-fold in TACI-negative mice) than day 6 post-
immunization. We speculate that the cycling B cells in the non-immunized mice are highly-
selected QM idiotype-negative (Id-) B cells (19) responding to a variety of environmental 
Ags producing diverse immunoglobulin (Ig). In contrast, after immunization with NP-Ficoll, 
Id+ B cells are synchronously stimulated and produce homogeneous Ig, which will give rise 
to immune complexes that inhibit Id+ B cell activation, decreasing the number of cycling B 
cells 6 days after immunization.   
 
To determine the extent to which TACI decreases B cell blasts after immunization, we 
analyzed spleen sections and splenocytes obtained from TACI-negative or TACI-positive 
QM mice by flow cytometry at days 4 and 6 after immunization. Mouse B cell blasts express 
an epitope recognized by a rat mAb, GL7. GL7 binds to sialylated glycans, the α-2,6-linked 
N-acetylneuraminic acid (Neu5Ac) on lactosamine glycan chains. Neu5Ac expression 
increases in germinal center B cells owing to repression of CMP-Neu5Ac hydroxylase which 
converts Neu5Ac to N-glycolylneuraminic acid (Neu5GC) that is not recognized by GL7. 
Naito et al. (21) showed recently that Neu5GC represses B cell activation, and therefore 
specific suppression of CMP-Neu5Ac hydroxylase enhances activation of germinal center B 
cells. T-independent stimulation of QM mice generates short-lived germinal centers that mark 
extensive B cell proliferation (22, 23). The number and size of GL7+ clusters was increased 
in TACI-negative mice 6 days after immunization (Figure 3b).  
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Figure 3 (cont.) 
E         F 
       
   
 
Figure 3.  TACI-negative QM B cells proliferate longer than TACI-positive B cells following 
immunization.   
(A)  DNA content of CD19+ B cells was determined by propidium iodide incorporation followed by 
fluorescence analysis with a FACScan flow cytometer and ModFiT LT software. Values are the 
proportion of B cells (CD19+) in the G2-S + M stage of the cell cycle at the time of immunization 
(basal), at day 4 or at day 6 postimmunization. Results were obtained with QM and QM-TACI-KO 
mice (each n= 3 for days 4 and 6) immunized with 30 µg of NP-Ficoll and sacrificed at the indicated 
times. *, Significant differences. (B) Spleen frozen sections obtained on day 6 after immunization, 
stained with anti-GL7 Abs to depict germinal centers (dark brown clusters in the follicle centers). 
TACI– mice have larger and more abundant clusters of GL7+ B cells at the center of the follicles 
(germinal centers) at day 6 postimmunization and increased numbers of GL7+ B cells 4 and 6 days 
after T-independent immunization. (C) and (D) Splenocytes were stained for GL7, CD138, and B220. 
(C) Typical flow cytometry plots representing lymphocyte distributions according to B220 and GL7 
expression of gated CD138– lymphocytes. Indicated in the diagrams are the gates used to determine 
the absolute and relative number of GL7+ B cells. (D) Number of GL7+B cells (B220+, GL7+, CD138–
) per spleen (left) or the percentage of GL7+ B cells. GL7 positivity was defined with an isotype 
control. Results are from three independent experiments. (E) and (F) Splenocytes were stained for 
annexin V, 7-aminoactinomycin D, and B220 to determine the frequency of apoptotic cells (annexin 
V+, 7-aminoactinomycin D–) after immunization. (E) Histograms represent annexin V fluorescence 
intensity of B220+ cells at days 4 and 6 postimmunization. (F) Number of annexin V+ B cells (annexin 
V+, 7-aminoactinomycin D–, and B220+) expressed as a percentage of annexin V+ B cells. TACI 
deficiency does not increase the number of apoptotic B cells in the spleen 4 and 6 days after 
immunization. FSC, Forward scatter. 
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 The proportion of follicles with GL7+ germinal centers was 88% in TACI-negative mice and 
only 51% in TACI-positive mice 6 days after immunization indicating enhanced late B cell 
proliferation in TACI-negative QM mice (Figure 3b). Consistently, the number and 
proportion of B cells (B220-positive) that are blasts (GL7+) was reproducibly increased in the 
absence of TACI after immunization (Figure 3c, d). More than 80% of the GL7+ B cells also 
expressed other germinal center markers such as Fas, bound the peanut agglutinin lectin, and 
were IgD-negative. These results suggest that TACI is necessary to stop cycling to allow 
terminal differentiation.  
 
 
TACI-deficiency caused impaired plasma cell differentiation owing to a B cell autonomous 
defect  
 
To determine whether the impaired Ab production in response to NP-Ficoll was owed to 
deficiency of TACI on B cells, we performed adoptive transfer experiments. Ten million QM 
B cells (CD19+) that have or lack TACI were transferred into RAG 1-/- recipients (n=5). At 
day 6 post immunization spleens from recipient mice had 16 (+/- 3.9) x106 or 16 (+/- 8.9) 
x106 QM TACI-positive or QM TACI-negative B cells on average, respectively. Recipients 
of QM TACI-positive B cells produced 2789 IgM and 999 IgG NP-specific ASCs per 
200.000 splenocytes, while recipients of QM TACI-deficient cells produced only 1561 IgM 
and 187 IgG NP-specific ASCs per 200.000 splenocytes (Figure 4). The number of NP-
specific ASCs in the bone marrow was > 10-fold reduced compared with the number in the 
spleen and did not differ in mice reconstituted with QM TACI-positive or with QM TACI-
negative B cells (Figure 4). These results indicate that expression of TACI by B cells suffices 
to enhance Ab production in response to TI-2 stimuli.   
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Figure 4.  QM B cell autonomous TACI deficiency impairs TI-2 antibody responses.   
Ten million purified CD19+ cells obtained from the spleens of QM or QM-TACI-KO mice were 
transferred into RAG1–/– mice (n=5 mice per cohort). One hour later, mice were immunized with 30 
µg of NP-Ficoll. The number of IgM or IgG ASCs was determined by NP-ELISPOT of splenocytes or 
bone marrow cells obtained from recipient mice 6 days after i.p. immunization. Recipients of TACI– 
QM B cells had only 1561 IgM or 187 IgG ASCs, whereas recipients of TACI+ B cells had 2789 IgM 
or 999 IgG ASCs per 200,000 B cells from the spleen. The results indicate that TACI deficiency 
causes a 1.8-fold decrease in the number of IgM-producing cells and 5.3-fold decrease in the number 
of IgG-producing cells in the spleen, 6 days after immunization. Recipients of TACI– B cells had 99 
IgM or 10.6 IgG ASCs, whereas recipients of TACI+ B cells had 111 IgM or 2.8 IgG ASCs per 
200,000 B cells in the bone marrow. *, Significant differences. 
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TACI-negative QM B cells were activated and proliferated as efficiently as TACI-positive 
QM B cells but had impaired plasma cell differentiation after stimulation in vitro.  
 
Our findings of severely reduced serum Abs and decreased Ab-secreting cell formation in 
response to immunization with NP-Ficoll suggested that TACI promotes Ab production. 
Defective Ab production in TACI-deficient QM mice could be owed to defective B cell 
activation, clonal expansion or terminal differentiation. To distinguish among these 
possibilities, we compared activation, proliferation and differentiation of TACI-negative or 
TACI-positive QM B cells in vitro. TACI-negative B cells were activated by 
lipopolysaccharide (LPS) or by NP-Ficoll to the same extent and with the same kinetics as 
TACI-positive B cells, as indicated by CD69 expression 20 hours later (Figure 5a), indicating 
that TACI is not required for activation of B cells. TACI-negative splenocytes proliferated 
more than TACI-positive splenocytes in response to LPS but not to NP-Ficoll (Figure 5b and 
5c, respectively). However, isolated TACI-negative or TACI-positive B cells proliferated 
equally in response to LPS (Figure 5b). Because LPS but not NP-Ficoll stimulates 
macrophages/monocytes and dendritic cells to produce TACI ligands (24), TACI inhibition 
of proliferation is only apparent in splenocyte cultures responding to LPS. It is possible that 
upon LPS stimulation macrophages/monocytes and dendritic cells express 
glycosaminoglycans that bind APRIL (25) enhancing its stimulatory function.  
 
The inhibitory properties of TACI do not account for the notably decreased Ab responses to 
TI-2 stimuli. To determine whether TACI promoted plasma cell differentiation, we analyzed 
expression of syndecan-1 (CD138, a marker of plasma cells) by TACI-positive or by TACI-
negative QM B cells by flow cytometry, 72 hours after stimulation. Figure 5d shows that the 
number of putative plasma cells (CD138+high) was 2-fold lower in cells lacking TACI than in 
TACI-positive cells. These results confirmed that TACI is required for efficient plasma cell 
differentiation. 
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Figure 5.  TACI-deficient QM B cells proliferate equally well but differentiate less than TACI-
proficient B cells following stimulation in vitro.   
(A) In vitro activation of QM and QM-TACI-KO B cells was assessed by surface expression of CD69 
20h after stimulation of splenocytes with 1 or 10µg/ml of LPS or NP-Ficoll, as indicated. Similar 
results were obtained in 4 independent experiments. (B) and (C)  Incorporation of [3H]TdR by 
splenocytes or B cells purified from the spleen cultured with LPS (0.1 µg/ml; (B)) or NP-Ficoll (0.1 
µg/ml; (C)), in the concentrations indicated, for 72 h. *, Significant differences. (D) Number of 
syndecan-1high, IgM+ in 1 million QM or QMTACI-KO splenocytes, cultured with 1 µg/ml NP-Ficoll, 
for 72 h. One of three experiments with similar results is shown. *, Significant differences. 
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Discussion 
 
Here we show that TACI expressed by B cells has a dual function. In support of this 
conclusion, we found that although Ag-stimulated B cells lacking TACI were normally 
activated in response to Ag, they proliferated longer and differentiated poorly into ASCs both 
in vivo and in vitro. Thus, we conclude that a defect in plasma cell differentiation is the cause 
for the deficient TI-2 Ab production in TACI-KO mice.  
 
TACI-negative QM mice produced normal levels of NP-specific IgM in response to NP-
Ficoll despite severely reduced IgM ASCs. These results suggest that in QM TACI-negative 
mice, serum IgM is not produced by terminally differentiated B cells (detected in ELISPOT). 
In fact, Abs can be made by B cells before terminal differentiation in relatively small 
amounts on a per cell basis (26). Thus, initial IgM Ab production depends greatly on the 
clonal size. Because we show that TACI-negative QM B cells proliferate to a greater extent 
and longer than TACI-positive QM B cells the clonal size must be larger in the absence of 
TACI. Therefore, the relatively normal early IgM responses by QM TACI-negative mice may 
be attributed to Ig secretion by non-plasma cells. Because IgG-producing cells arise later, 
switched cells are a minority in the clone, and thus the IgG serum level is mostly the product 
of plasma cells. As TACI promotes differentiation into plasma cells, IgG plasma cells are 
decreased in TACI-negative relative to TACI-positive mice, explaining the severely reduced 
IgG serum levels. It is possible that accelerated proliferation of TACI-KO B cells, in fact, 
contributes to their decreased ability to differentiate, as is thought to occur in B cells of p18 
KO mice (27). 
 
Our results explain how human subjects with common variable immunodeficiency (CVID) 
owing to mutations of TACI have specific defects in the production of switched Ig isotypes 
with an intact class switching mechanism (28, 29). In these patients, a larger initial clonal size 
composed mainly of undifferentiated IgM-positive B cells would account for the relatively 
normal IgM levels. In contrast to IgM producing cells, B cells secreting switched isotypes are 
much less frequent, and therefore the serum level of switched isotypes is mostly owed to 
differentiated plasma cells. Thus, excessive expansion and impaired differentiation of B cells 
in TACI-defective subjects results in switched Ig isotype defects (28, 29). 
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T-independent activation of B cells induces activation induced cytidine deaminase (AID) 
expression (30), somatic hypermutation (23), and germinal center formation (22), and 
therefore may potentially originate auto-reactive Abs. How the generation of auto-reactive 
Abs is prevented following T-independent stimuli is not known. Assuming that AID is 
expressed and the rate of mutation is maintained during clonal expansion, mutants will 
accumulate in an exponential manner (31). Thus, increased clonal sizes owing to TACI-
deficiency may increase substantially the number of B cells producing mutated and auto-
reactive Abs in response to T-independent stimulation. Thus, TACI may limit the 
development of auto-reactive Abs by decreasing clonal expansion and because plasma cells 
do not mutate, by promoting rapid differentiation. Our results indicate that engagement of 
TACI promotes termination of proliferation and plasma cell differentiation, limiting the 
chances of forming auto-reactive Abs following T-independent stimulation. This possibility 
is in agreement with the findings of Grewal and collaborators, who showed increased 
incidence of autoimmune Abs in aged TACI-KO mice (17).  
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The subject of the second part of this work was to understand how TACI promotes antibody 
production. In order to determine the mechanism by which TACI controls antibody responses 
to polysaccharides, whether and how TACI promotes QM B cell responses to a 
polysaccharide like T-independent antigen, the response of engineered QM TACI KO to NP-
Ficoll was investigated.  
 
It was documented that QM mice that lacked TACI produced decreased numbers of IgM (4-
fold) and IgG (2.5-fold) NP-specific antibody-secreting cells (ASCs), compared to TACI-
positive QM mice in response to immunization with NP-Ficoll (1). Thus, these results 
indicated that TACI may act at a remote time from activation since TACI was not necessary 
for activation and proliferation of B cells both in vitro and in vivo. Instead, TACI-deficient 
QM B cells remained in the cell cycle longer than TACI-proficient QM cells and had 
impaired plasma cell differentiation in response to NP-Ficoll (1). 
 
In conclusion, TACI has dual B cell-autonomous functions, inhibiting prolonged B cell 
proliferation and stimulating plasma cell differentiation, thus resolving the longstanding 
paradox that TACI may have both B cell inhibitory and stimulatory functions. By promoting 
plasma cell differentiation earlier during clonal expansion, TACI may decrease the chances 
of auto-antibody production by somatic hypermutation of immunoglobulin genes in response 
to T-independent antigens.  
 
These findings showing that TACI stimulates plasma cell differentiation may explain how 
human subjects with common variable immunodeficiency owing to mutations of TACI have 
specific defects in the production of switched Ig isotypes with an intact class switching 
mechanism (2, 3). In these patients, a larger initial clonal size composed mainly of 
undifferentiated IgM+ B cells would account for the relatively normal IgM levels.  In contrast 
to IgM-producing cells, B cells secreting switched isotypes are much less frequent, and 
therefore the serum level of switched isotypes is mostly owed to differentiated plasma cells. 
Thus, excessive expansion and impaired differentiation of B cells in TACI-defective subjects 
results in deficient secretion of switched Ig isotypes (2, 3).  
 
 
 192 
 
Part II – Conclusions and Future Perspectives 
Compromised responses to encapsulated microbes and polysaccharides in subjects with 
CVID owing to TACI-deficiency are compatible with B cell autonomous defects since 
antibody responses to polysaccharides are thought to occur independently of T cell help. It is 
possible that differentiation to plasma cells may also be compromised in response to protein 
antigens which require T cell help, explaining the serum antibody paucity in subjects with 
CVID owing to TACI deficiency. Alternatively TACI deficiency may impair T cell help to B 
cells compromising antibody response to proteins.  
These data further support an important role for TACI in the differentiation of plasma cells, 
and its possible relevance as a target for immune based therapies not only in the context of 
CVID but also in autoimmunity and B cell neoplasias. 
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